



UNIVERSITÀ
DEGLI STUDI
FIRENZE

FLORE

Repository istituzionale dell'Università degli Studi di Firenze

Exploration of Nitrogen Heterocycle Scaffolds for the Development of Potent Human Neutrophil Elastase Inhibitors

Questa è la Versione finale referata (Post print/Accepted manuscript) della seguente pubblicazione:

Original Citation:

Exploration of Nitrogen Heterocycle Scaffolds for the Development of Potent Human Neutrophil Elastase Inhibitors / Cantini, Niccolò; Khlebnikov, Andrei I.; Crocetti, Letizia; Schepetkin, Igor A.; Floresta, Giuseppe; Guerrini, Gabriella; Vergelli, Claudia; Bartolucci, Gianluca; Quinn, Mark T.; Paola Giovannoni, Maria. - In: BIOORGANIC & MEDICINAL CHEMISTRY. - ISSN 0968-0896. - ELETTRONICO. - 29:(2021), pp. 1-17. [10.1016/j.bmc.2020.115836]

Availability:

This version is available at: 2158/1215319 since: 2021-09-30T13:19:53Z

Published version:

DOI: 10.1016/j.bmc.2020.115836

Terms of use:

Open Access

La pubblicazione è resa disponibile sotto le norme e i termini della licenza di deposito, secondo quanto stabilito dalla Policy per l'accesso aperto dell'Università degli Studi di Firenze (<https://www.sba.unifi.it/upload/policy-oa-2016-1.pdf>)

Publisher copyright claim:

Conformità alle politiche dell'editore / Compliance to publisher's policies

Questa versione della pubblicazione è conforme a quanto richiesto dalle politiche dell'editore in materia di copyright.

This version of the publication conforms to the publisher's copyright policies.

(Article begins on next page)



Published in final edited form as:

Bioorg Med Chem. 2021 January 01; 29: 115836. doi:10.1016/j.bmc.2020.115836.

Exploration of nitrogen heterocycle scaffolds for the development of potent human neutrophil elastase inhibitors

Niccolò Cantini^a, Andrei I. Khlebnikov^{b,c}, Letizia Crocetti^{a,*}, Igor A. Schepetkin^d, Giuseppe Floresta^e, Gabriella Guerrini^a, Claudia Vergelli^a, Gianluca Bartolucci^a, Mark T. Quinn^d, Maria Paola Giovannoni^a

^aNEUROFARBA, Pharmaceutical and Nutraceutical Section, University of Florence, Sesto Fiorentino, Italy

^bNational Research Tomsk Polytechnic University, Tomsk 634050, Russia

^cFaculty of Chemistry, Tomsk State University, Tomsk 634050, Russia

^dDepartment of Microbiology and Immunology, Montana State University, Bozeman, MT, USA

^eInstitute of Pharmaceutical Science, King's College London, Stamford Street, London SE1 9NH, UK

Abstract

Human neutrophil elastase (HNE) is a potent protease that plays an important physiological role in many processes but is also involved in a variety of pathologies that affect the pulmonary system. Thus, compounds able to inhibit HNE proteolytic activity could represent effective therapeutics. We present here a new series of pyrazolopyridine and pyrrolopyridine derivatives as HNE inhibitors designed as modifications of our previously synthesized indazoles and indoles in order to evaluate effects of the change in position of the nitrogen and/or the insertion of an additional nitrogen in the scaffolds on biological activity and chemical stability. We obtained potent HNE inhibitors with IC₅₀ values in the low nanomolar range (10–50 nM), and some compounds exhibited improved chemical stability in phosphate buffer ($t_{1/2} > 6$ h). Molecular modeling studies demonstrated that inhibitory activity was strictly dependent on the formation of a Michaelis complex between the OH group of HNE Ser195 and the carbonyl carbon of the inhibitor. Moreover, *in silico* ADMET calculations predicted that most of the new compounds would be optimally absorbed, distributed, metabolized, and excreted. Thus, these new and potent HNE inhibitors represent novel leads for future therapeutic development.

*Corresponding author at: Department of NEUROFARBA, Via Ugo Schiff 6, Sesto Fiorentino, 50019 Firenze, Italy. letizia.crocetti@unifi.it (L. Crocetti).

Author Contributions

Crocetti L. and Giovannoni M.P. designed the compounds and wrote the manuscript; Cantini N., Guerrini G., Vergelli C., and Bartolucci G. synthesized and characterized the compounds, wrote the experimental section, and checked the final version of the manuscript. *In vitro* studies (inhibition assay) and analysis of stability were performed by Schepetkin I.A. and Quinn M.T. Molecular docking, DFT calculations, and the corresponding analysis of data were performed by Khlebnikov, A.I. All authors participate in revisions and have given approval of the final manuscript version.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Appendix A. Supplementary material

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.bmc.2020.115836>.

Keywords

Human neutrophil elastase; Inhibitors; Nitrogen heterocycle; Stability; ADMET; Molecular docking

1. Introduction

Heterocyclic nuclei are considered privileged scaffolds in medicinal chemistry, and a wide variety of combinations of nitrogen, sulfur, and oxygen atoms in five- and six-membered rings have been reported. Notably, nitrogen heterocycles play a central role in drug discovery and are represented in ~85% of all biologically active chemical molecules. Furthermore, the number and the position of the nitrogen atoms in the ring influence some pharmacokinetic properties, such as solubility, hydrophilic/lipophilic characteristics, and the ability to form hydrogen bonds.¹ We have identified a number of heterocyclic scaffolds that were modified based on the desired protein target in order to increase the number or the strength of the interactions with a catalytic site or receptor binding domains.²⁻⁵ For example, the identification and modification of nitrogen heterocycles has been essential in the discovery of new potent inhibitors of human neutrophil elastase (HNE), a proteolytic enzyme belonging to the serine protease family. This enzyme is involved in a variety of chronic diseases, including cardiopulmonary pathologies,⁶ and its regulation represents a promising therapeutic approach, as evident by the interest of many pharmaceutical companies. In fact, research in this field is quite active, and a number of HNE inhibitors are currently in various stages of clinical trials,⁷ such as Alvelestat developed by AstraZeneca in various formulations⁸, BAY85-8501 in phase II trials for bronchiectasis (Bayer HealthCare),⁹ and CHF6333, a novel potent inhaled HNE inhibitor by Chiesi Farmaceutici, in phase I trials for cystic fibrosis.^{10,11} Currently, only two HNE inhibitors are on the market. The first one, Prolastin® (purified α 1-AT), is a peptide drug used in the treatment of α 1-AT deficiency.¹² The second is Sivelestat (ONO-5046, Elaspol® 100), a non-peptide inhibitor approved for intravenous use in Japan and South Korea for the treatment of ALI and ARDS associated with systemic inflammatory response syndrome.¹³

We have designed and synthesized a number of potent HNE inhibitors with various scaffolds.¹⁴⁻¹⁸ Among these compounds, the indazole and 7-azaindole nuclei resulted the best nitrogen bicycles, including HNE inhibitors active in the low nanomolar range.¹⁹⁻²² Based on these previous studies, we report here new HNE inhibitors that were developed through modification of the indazole and 7-azaindole (1H-pyrrolo[2,3-*b*]pyridine) nuclei in order to determine if the introduction of another nitrogen atom and/or moving nitrogen from its original position could affect biological activity (Fig. 1). The profile of selected compounds was further examined in depth with stability and molecular modeling studies. Moreover, *in silico* pharmacokinetic (ADMET) profiles of the most potent HNE inhibitors obtained ($IC_{50} < 1 \mu M$) were evaluated in order to identify candidates for future *in vivo* studies.

2. Results and discussion

Two different strategies were pursued in our studies: 1) insertion of an additional nitrogen atom at position 5 or 7 of the indazole nucleus, resulting in 5- and 7-azaindazole derivatives (1H-pyrazolo[3,4-*b*]pyridine and 1H-pyrazolo[4,3-*c*]pyridine) (Fig. 1A) and insertion at position 4 of the 7-azaindole nucleus, resulting in 5H-pyrrolo[2,3-*b*]pyrazines (Fig. 1B); and 2) moving the nitrogen in the pyrrolopyridine scaffold from position 7 to positions 4, 5, and 6 of the pyridine ring (Fig. 1B). Finally, we synthesized some pyrazolopyrimidines containing an exocyclic amide group instead of the endocyclic amide function present in all of our previous compounds. In all new compounds, we inserted those fragments and substituents that lead to the optimal biological results based on our previous studies and those reported in the literature.

2.1. Chemistry

All compounds were synthesized as reported in Schemes 1–5, and the structures were confirmed on the basis of analytical and spectral data. To obtain the 3-substituted derivatives of the 5- and 7-azaindazoles, we followed the procedures shown in Scheme 1 and 2. Starting from the previously described compounds of type **1** (**1a,b**,²³ **1c,d**,²⁴ **1e,f**,²⁵ **1g**²⁶ and **1h**²⁷), we synthesized the final compounds **2a-t** (Scheme 1) following the indicated reaction conditions. Treatment with *m*-toluoyl chloride or cyclopropanecarbonyl chloride, triethylamine in anhydrous dichloromethane at room temperature resulted in synthesis of compounds **2a,b,l-o,r-t**, while derivatives **2e-i,p,q** are obtained using sodium hydride in dry tetrahydrofuran at room temperature. Compound **2c** was obtained starting from intermediate **1b** using benzyl bromide and potassium carbonate in dry acetonitrile at reflux, whereas **2d** was obtained using benzoic acid, activating reagents (OHBT and DCC) and triethylamine in dry tetrahydrofuran.

Scheme 2 shows synthesis of the pyrazolo[3,4-*b*]pyridine derivatives containing a nitro (**4**), an amino (**6**), or an amide group (**7–9**) at position 3. The 3-nitro derivative **4** was obtained through an acylation reaction starting from compound **3**²⁸ and following the procedure previously reported in Scheme 1. Reduction of the nitro group in compound **3** with tin(II) chloride in acid medium, led to intermediate **5**²⁸ in high yield, which was then treated with 3-methylbenzoyl chloride, triethylamine in 1,4-dioxane and DMF. According to the results reported in the literature for pyrazolo-quinolines,²⁹ acylation selectively occurred on the amino group at position 3 under these conditions, resulting in the final compound **8**. Compound **8** was further treated with acetyl chloride under the conditions shown in Scheme 1 to obtain the final derivative **9**. Different results were observed when intermediate **5** was reacted with cyclopropanecarbonyl chloride, since a mixture of mono-acyl **6** and bi-acyl derivative **7** was obtained.

Scheme 3 shows the synthetic pathway used to obtain the pyrrolopyridines **13a-f**. The starting material **10a-c** (**10a,b**³⁰ and **10c**³¹) was treated with hydroxylamine hydrochloride and NaHCO₃ at high temperature, leading to the corresponding oximes **11a-c** (**11c**³²). Dehydration with POCl₃ resulted in the 3-CN derivatives **12a-c** (**12c**³²), which were finally

acylated at position 1 with the appropriate acyl (aroyl) chloride and triethylamine in anhydrous dichloromethane to obtain the azaindoles **13a-f**.

The synthesis of compounds with a 5H-pyrrolo[2,3-*b*]pyrazine scaffold (**15a,b** and **19a,b**) is shown in Scheme 4. The final compounds **15a,b** were obtained starting from intermediate **14**³³ and following the acylation procedures described above. To obtain compounds **19a,b**, the CN group was inserted at position 3 as follows: formylation of compound **14** with HTMA and glacial acetic acid (**16**³³), transformation into the corresponding oxime (**17**), and dehydration to compound **18**, which was subjected to acylation. Unfortunately, compounds **15a** and **19a**, which contained a *m*-toluoyl fragment at position 1, were not chemically stable and quickly turn into the precursors **14** and **18** at room temperature, respectively.

Scheme 5 shows the steps leading to synthesis of the pyrazolopyrimidine derivatives **22a-h**. Part a of Scheme 5 shows the synthesis of pyrazolopyrimidines containing the amide function at position 6, and Part b shows synthesis of the final compounds **22 g,h** displaying the amide group at position 3 of the bicyclic scaffold. Starting with compounds **20a,b**³⁴ and **20d**³⁵, which were previously described, or compound **20c**, which was obtained from **20b** through chlorination with *N*-chlorosuccinimide (NCS) and benzoyl peroxide in tetrachloromethane at reflux, the 6-carbethoxy (**20a-c**) and 3-carbethoxy (**20d**) derivatives were hydrolyzed using 6 N NaOH at reflux, resulting in the corresponding acids **21a-d** (**21a,b,d**³⁶⁻³⁸). These compounds were treated with trichloroacetonitrile, triphenylphosphine and *m*-anisidine or 3-methoxybenzylamine to obtain the final compounds **22a-h**.

2.2. Biological evaluation and structure-activity relationship (SAR) analysis

All compounds were evaluated for their ability to inhibit HNE, and the results are presented in Tables 1–3, together with data from representative reference compounds from the previous series of *N*-benzoylindazoles (**A**²⁰), 7-azaindoles (**B**²¹ and **C**²¹), and the drug Sivelestat. Keeping the cyano group that is present in the reference indazole **A** at position 3 of the 7-azaindazole compounds, we introduced various substituents at position 1 (Table 1). The introduction of a phenyl (**2d**) or cyclopentyl (**2 h**) ring resulted in retention of HNE inhibitory activity (IC₅₀ = 140 and 160 nM, respectively), whereas introduction of a cyclohexyl ring resulted in loss of activity for compound **2i**. The 7-aza analogue of compound **A** displaying a *m*-toluoyl fragment at 1-N (**2e**), was 47 fold less potent than **A** (**2e**: IC₅₀ = 330 nM versus **A**: IC₅₀ = 7 nM). Isomer **2f** obtained by the shift of the methyl group from the *meta* to the *para* position was even less active (IC₅₀ = 1.5 μM). The best compound of the 3-CN derivatives was **2 g**, which contains a cyclopropyl group at the amide function (IC₅₀ = 34 nM). Elimination of the amide function led to complete loss of HNE inhibitory activity (compound **2c**), confirming the importance of this group in the catalytic mechanism. Replacement of the cyano group at position 3 with various groups or functions selected from our previous publications or from the literature also gave interesting results. Ester (**2 l,m**), amine (**6**), amide (**7**, **9**) derivatives were only moderately active, with HNE inhibition in the micromolar range. In contrast, introduction of the trifluoromethyl (**2a,b**) or the nitro group (**4**) led to potent HNE inhibitors, with IC₅₀ values comparable to or better than that of Sivelestat (**2b**, IC₅₀ = 50 nM; **4**, IC₅₀ = 21 nM). Thus, the most active compounds in the 7-azaindazole series were **2b**, **2 g** and **4**, which contain common elements,

including a group cyclopropyl at the amide function and the presence of a strong electron withdrawing group at position 3 (i.e., CN, CF₃, or NO₂).

Analysis of the 5-azaindazole derivatives (**2n-t**) revealed a slightly different trend. First, the substitutions with CF₃ or CN groups (compound **2n-q**), as well as the weaker electron withdrawing ester group (**2r,s**), were tolerated, resulting in potent HNE inhibitors (IC₅₀ = 10–87 nM). On the other hand, substitution with a methyl group (**2t**) resulted in significant loss of activity (IC₅₀ = 760 nM). In addition, replacement with an *m*-toluoyl fragment resulted in compounds with the highest activity, as is evident when comparing these pairs: **2n/2o**, **2p/2q**, and **2r/2s**, which was different from the trend observed with the 7-azaindazoles. Compound **2p**, which is the 5-aza analogue of **A**, is the most potent compound of this series, had comparable activity with **A** (IC₅₀ = 10 nM).

Modification of the azaindoles **13a-f**, which are isomers of the 7-azaindoles **B** and **C** and the pyrrolopyrazines of type **15** and **19**, led to the formation of highly active derivatives (Table 2). Specifically, movement of the nitrogen in the pyridine ring from position 7 of **B** and **C** to position 4 or 5 resulted in compounds with IC₅₀ values of 14–97 nM, with **13c** being the best term of this series. In contrast, shift of the nitrogen to position 6 (compounds **13e** and **13f**) led to reduced activity compared to the reference compounds **B** and **C**, indicating that the nitrogen in this position does not interact well with the target. The pyrrolopyrazine **19a**, which differs from the reference compound **C** by the introduction of a second nitrogen at position 4, retained high HNE inhibitory activity (IC₅₀ = 56 nM), whereas elimination of the CN at position 3 (compound **15**) resulted in reduced activity by two orders of magnitude.

The pyrazolopyrimidine derivatives **22a-h** containing an exocyclic amide group instead of an endocyclic amide function were all completely inactive, indicating that this modification was not tolerated (Table 3).

The 12 most potent HNE inhibitors were evaluated for their chemical stability in aqueous buffer.³⁹ Spontaneous hydrolysis rates and reaction orders of the inhibitors were measured in phosphate buffer at pH 7.4 and 20 °C using spectrophotometry to detect compound hydrolysis. As examples, Fig. 2 shows that the absorbance maxima at 305 nm decreased over time for compound **4**, while a new peak appeared at 255 nm.

As shown in Table 4, compounds **2b**, **2o**, **2s**, and **13b** were the most stable with $t_{1/2} > 4$ h. We found that compounds containing a cyclopropyl group at position 1 (compounds **2s** and **13b**) were more stable when compared to the analogs with a *m*-toluoyl substituent (compounds **2r** and **13a**, respectively). Conversely, the azaindazole derivatives (series **2** with 3 nitrogen atoms in the heterocycle) were more stable than the azaindoles and indazoles (2 nitrogen atoms in the heterocycle). Moreover, the most stable compound **2b** had a CF₃ at position 3 (compared to compounds **2q** and **2s** with CN and COOEt groups, respectively). Noticeably, acceptor substituents at position 3 exhibiting mesomeric effects with respect to the heterocyclic moiety (CN and NO₂) were present in mostly unstable or moderately unstable compounds (e.g., **2p**, **2q**, **4**, **13a**, **13c**, **19b**). This observation is in agreement with amide hydrolysis according to the well-known acyl substitution mechanism,⁴⁰ which includes a nucleophilic attack on the carbonyl carbon atom in the rate-limiting step. In

addition, it should be mentioned that *N*-acyl derivatives of azoles are highly reactive amides, as compared to other compounds containing an amide function.^{41,42}

In general, it was difficult to find a clear relationship between hydrolytic activity and electronic or steric effects of the heterocyclic moieties and substituents within the series of the investigated compounds. However, we found that the observed hydrolytic instability could be explained by the energies of the lowest unoccupied molecular orbital (LUMO) calculated for the optimized geometries of compounds **2b**, **2n**, **2o**, **2p**, **2q**, **2r**, **2s**, **4**, **13a**, **13b**, **13c**, and **19** using density functional theory (DFT) (Table 4). The optimized structures of cyclopropyl-containing compounds, except for **13b**, have C_s symmetry with heterocyclic and cyclopropane groups lying in mutually perpendicular planes. For toluoyl-substituted derivatives, the angle between the planes of the heterocycle and *m*-tolyl group varied between 30 and 50°. Relatively stable compounds **2b**, **2o**, **2s**, and **13b** can be distinguished from hydrolytically unstable derivatives according to their LUMO energies E(LUMO) (Fig. 1S, see Supplementary Material). The unstable compounds had systematically lower values of E(LUMO) and, hence, were more prone to reactions with nucleophiles. This conclusion agrees with the above-mentioned mechanism of the base-catalyzed hydrolysis involving an attack of the hydroxide anion on the carbonyl group. It should be noted that LUMO has a significant localization at the carbonyl carbon atom in both stable and unstable compounds (see examples in Fig. 3) and, thus, its energy can strongly affect electrophilicity of the carbonyl group. The relationship between E(LUMO) and hydrolytic stability is not quantitative, (i.e., LUMO energy is not tightly correlated with $t_{1/2}$ or rate constant k'). Clearly, reactivity is determined not just by the electronic structure of a starting compound but is also highly dependent on properties and stability of the tetrahedral intermediate formed on the addition of the hydroxide ion to the carbonyl group in the rate-limiting step.

Classification of stable and unstable compounds according to other calculated characteristics, such as energy of the highest occupied molecular orbital (HOMO), LUMO-HOMO energy gap, or some local indices of reactivity (e.g., atomic charges, Wiberg index for the amide bond) did not lead to a separation similar to the result presented in Fig. 1S for LUMO energies.

2.3. Molecular modeling

We performed molecular modeling of selected compounds in the active site of HNE (1HNE entry of Protein Data Bank) using previously reported methods.^{20,21} According to the literature,⁴³ inhibitors interact with HNE via a nucleophilic attack of the Ser195 hydroxyl oxygen atom onto a carbonyl carbon atom of a ligand, which leads to the formation of a Michaelis complex. This interaction is accompanied by proton transfer from Ser195 to Asp102. For the docking poses obtained, we have evaluated the geometric parameters d_1 and α , which are important for Michaelis complex formation (Fig. 4). In addition, length of the proton transfer channel within the catalytic triad from Ser195 to Asp102 through His57 was calculated using d_2 and d_3 distances between the key atoms (see *Methods*).

Compounds **2e** (IC₅₀ = 330 nM) and **2p** (IC₅₀ = 10 nM) contain an additional nitrogen atom at different positions of the fused aromatic ring compared to compound **A**.²⁰ The docking poses of these molecules are shown in Fig. 5. Although these three molecules are

isosteric, the presence of an additional nitrogen atom in the heterocycle of compounds **2e** and **2p** favors arrangement of their bicyclic fragments among polar amino acid residues versus compound **A** with an indazole heterocycle. Molecule **2e** forms a H-bond with Val216 via participation of the nitrogen atom at position 7 of the heterocycle, while compound **2p** is H-bonded to Ser195 with two nitrogen atoms of the five-membered ring. In addition, strong H-bonds are formed between the carbonyl oxygen of **2p** and Gly193 and Ser195. Note that the nitrogen atom at position 5 of the heterocycle in **2p** is located near an electropositive (blue) region of the binding site surface (Fig. 5D), which should, along with the H-bonds, stabilize the molecule in the obtained docking pose.

Compound **4** containing nitro and cyclopropyl groups is anchored in the HNE binding site due to H-bonds with Val216 (with the participation of the nitro group), Gly193, and Ser195 (with the participation of the amide oxygen atom) (Fig. 6A). Compound **2r** has two potential centers for nucleophilic attack by Ser195 (i.e., carbonyl oxygen atoms of the amide and ester groups). H-bonds with Gly193 formed with participation of the amide oxygen atom and one of the nitrogen atoms in the five-membered ring play a role in anchoring **2r** inside the binding site (Fig. 6B). The d_1 distances $O=C\cdots O(\text{Ser195})$ in the pose obtained for compound **2r** are 2.946 and 3.817 Å for the carbonyl carbon atoms of the ester and amide groups, respectively (Table 5). From this point of view, nucleophilic attack on the ester group is more likely. In addition, the angle α in this case is 86.7°, being in the range of 80–120°, which is favorable for formation of the Michaelis complex,^{44–46} which is in contrast to $\alpha = 132.9^\circ$ obtained for the amide C=O bond.

A comparative analysis of molecules containing one nitrogen atom in the five-membered ring (**13a**, **13c**, **13e**, and **B²¹**) shows that they have a somewhat similar orientation within the binding site (Fig. 7A). Both heterocyclic and *m*-methylbenzoyl groups were located approximately in the same corresponding regions of space inside the enzyme. Some features of their interactions with the HNE amino acids should be mentioned and are illustrated in Fig. 7. Compounds of this series form H-bonds with Gly193 involving participation of the amide oxygen atom (**13e** and **13c**), or with Ser195 involving participation of the oxygen and nitrogen atoms of the amide function (**13e** and **13a**). In addition, compound **13a** is H-bonded to Val216 via the nitrogen atom at position 4 of the heterocycle. A comparison of the docking poses of compounds **13c** and **2p**, of which the latter has an additional nitrogen atom in the five-membered ring instead of the CH group, showed a slight difference in orientation of the molecules within the binding site (not shown). Although positions of cyano and carbonyl groups of these compounds are close in space, the heterocyclic and *m*-toluoyl fragments do not mutually coincide. Obviously, the difference in the arrangement of **2p** and **13c** docking poses is due to peculiarities of the **2p** H-bonding pattern (Fig. 7, panel C).

Table 5 shows the geometric parameters (distance d_1 and angle α) for the docking poses, as well as the distances d_2 and d_3 between the key atoms of the catalytic triad of Ser195, His57, and Asp102 (Fig. 4), which determine the length *L* of the proton transfer channel. Values of α for most of the compounds evaluated were between 80 and 120° and are optimal for formation of the Michaelis complex. The exceptions were the less active compounds **2e** and **13e**. The pose of another compound with reduced activity (**13a**) is characterized by an angle

α close to 80°; however, the proton transfer channel L for this molecule has a rather high value due to mutual displacements of the residues of the catalytic triad upon binding of **13c** to HNE.

2.4. ADMET assessment

To facilitate selection of lead compounds and to further support the molecular modelling and *in vitro* evaluation, we also performed an *in silico* absorption, distribution, metabolism, and excretion-toxicity (ADMET) pharmacokinetics evaluation. The *in silico* assessment was generated through the evaluation of pharmacokinetic profiles and possible adverse side effects for compounds **2a-t**, **4**, **6**, **7**, **9**, **13a-f**, **15**, and **19**. ADMET molecular studies were conducted using SwissADME (<http://swissadme.ch>)⁴⁷ and pkCSM (<http://biosig.unimelb.edu.au/pkcsm/>)⁴⁸ (see Supplemental Tables 1S–10S). Most of the compounds were predicted to be orally available, with high gastrointestinal absorption and high water solubility (Tables 2S, 3S). Compounds with predicted moderate solubility (10⁻⁵ mol/L range) were **2a**, **2i**, **2l**, **2m**, **2n**, and **2r**. Only compounds **2o**, **6** and **7** were predicted to be P-glycoprotein substrates, whereas most of the compounds were predicted to be inhibitors of the CYP1A2. Some compounds were also predicted to inhibit CYP2C19/CYP2C9, but no inhibition was predicted for CYP3A4 and CYP2D6. Otherwise, most of the compounds were predicted to be CYP3A4 substrates but should not be metabolized by CYP2D6 (Table 7S). Interestingly, none of the compounds violated the Lipinski rule of 5, nor did they violate the other drug-likeness rules (Ghose, Egan, Veber, and Muegge).^{49–53}

The absorption and distribution calculated parameters are shown in an Egan–Egg model (Fig. 8) (Brain or Intestinal Estimated, BOILED-Egg). The Egan–Egg model highlights that most of the compounds were predicted to passively permeate the blood-brain barrier, whereas compounds **2g**, **2q**, **2s**, **4**, **6**, **7**, and **19** are only able to be passively absorbed by the gastrointestinal tract pkCSM calculated absorption properties showed > 95% intestinal absorption (aside from molecule **6** with 77.3%), due to the calculated optimal (>0.90) Caco-2 cell permeability (Table 5S). Moreover, most of the compounds are predicted to be adsorbed by the skin (exploitable for transdermal drug delivery) as shown by the Log Kp < -2.5 (see skin permeability, Table 5S).

The calculated values of steady state volume of distribution are relatively low for some compounds (Log VD_{ss} < -0.15, Table 6S), but most of the compounds were predicted to have a significant unbound fraction in the plasma, thus becoming available for interaction with the pharmacological target (Table 6S). The calculated values of the total clearance (Table 8S) indicate that most of the compounds were predicted to have good renal elimination (0.20–0.84 mL/min/kg), and no compounds were predicted to be substrates of the renal organic cation transporter 2. pkCSM calculated toxicity properties indicated concerns about the AMES test, the *T. pyriformis* toxicity and hepatotoxicity. On the other hand, the compounds did not have skin sensitization properties and were not predicted to be inhibitors of hERG I and II (Table 9S). Due to the toxicology concerns indicated by pkCSM, toxicology was also evaluated with Datawarrior (v. 5.2.1 <http://www.openmolecules.org/datawarrior/>). In this case, all compounds were predicted to be non-mutagenic, non-tumorigenic, and not irritants. A low risk for reproductive

system effects was associated with molecules **2l-n** and **2r,s** (Table 10S). *In silico* toxicity evaluations were also performed with preadmet (<https://preadmet.bmdrc.kr/toxicity/>) and admetsar1 (<http://lmmd.ecust.edu.cn/admetsar1>). The results for preadmet are presented in Table S11, while the results for admetsar1 are presented in Tables 12S–41S. Preadmet considered most of the compounds mutagenic in the same test, whereas admetsar1 considered most of the compounds as nontoxic in the same test. Despite this result, most of the compounds were considered non-carcinogenic for mouse or rat, with a medium to low risk for their hERG inhibition in both *in silico* evaluations. Further biological evaluation is needed due to the somewhat contrasting test results, but the ADMET general profile was good for our set of compounds, particularly the most potent compounds **2p**, **2r**, **4**, **13b**, and **13c**, which had excellent ADMET profiles and shouldn't have any particular toxicity issues. The IC₅₀ measured potency, together with the ADMET profile will be of fundamental importance for the future selection of compounds for *in vivo* evaluation.

3. Experimental section

3.1. Chemistry

All melting points were determined on a Büchi apparatus (New Castle, DE) and are uncorrected. Extracts were dried over Na₂SO₄, and the solvents were removed under reduced pressure. Merck F-254 commercial plates (Merck, Durham, NC) were used for analytical TLC to follow the course of reactions. Silica gel 60 (Merck 70–230 mesh, Merck, Durham, NC) was used for column chromatography. ¹H NMR and ¹³C NMR spectra were recorded on an Avance 400 instrument (Bruker Biospin Version 002 with SGU, Bruker Inc., Billerica, MA). Chemical shifts (δ) are reported in ppm to the nearest 0.01 ppm using the solvent as an internal standard. Coupling constants (*J* values) are given in Hz and were calculated using TopSpin 4.0.8 software (Nicolet Instrument Corp., Madison, WI) and are rounded to the nearest 0.1 vHz. High resolution mass spectrometry (HRMS) analysis was performed with a Thermo Finnigan LTQ Orbitrap mass spectrometer equipped with an electrospray ionization source (ESI). The solvents used in HRMS were acetonitrile (Chromasolv grade) purchased from Sigma-Aldrich (Milan, Italy) and mQ water 18 M Ω cm, obtained from Millipore's Simplicity system (Milan, Italy). The accurate mass measure was performed by introducing sample solution (1.0 μ g mL⁻¹ in mQ water: acetonitrile 50:50) via syringe pump at 10 μ L min⁻¹, and the signal of the positive ions was acquired. The experimental conditions allowed monitoring of the protonated molecules ([M + H]⁺ species) with a proper dwell time to achieve 60,000 units of resolution at full width at half maximum (FWHM). Microanalyses indicated by the symbols of the elements or functions were performed with a Perkin–Elmer 260 elemental analyzer (PerkinElmer, Inc., Waltham, MA) for C, H, and N, and the results were within \pm 0.4% of the theoretical values, unless otherwise stated. Reagents and starting material were commercially available.

3.1.1. General procedure for compounds (2a,b, 2l-o, and 2r-t)—To a cooled (0 °C) suspension of the appropriate substrate **1a**,¹⁷ **1c**, **d**,¹⁸ **1e**,¹⁹ **1g**,²⁰ or **1h**²¹ (0.32 mmol) in anhydrous CH₂Cl₂ (2 mL), 0.64 mmol of Et₃N and 0.96 mmol of the appropriate acyl/aroyl chloride were added. The mixture was stirred at 0 °C for 2 h and then at room temperature for an additional 2 h. The solvent was evaporated, cold water was added, and the mixture

was neutralized with 0.5 N NaOH. The reaction mixture was extracted with CH₂Cl₂ (3 × 15 mL), the solvent was dried over sodium sulfate and evaporated in vacuum. The final compound **2o** was purified by crystallization with ethanol while the compounds **2a,b,l-n,r-t** were purified by flash column chromatography using cyclohexane/ethyl acetate 3:1 (**2a,b,n**) or 1:1 (**2s,t**), hexane/ethyl acetate 5:2 (**2l,m**), dichloromethane/methanol 9:1 (**2r**) as eluents. Finally, all compounds were crystallized from ethanol, and melting points were performed after crystallization.

m-Tolyl(3-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-1-yl) methanone (2a): Yield = 26%; mp = 67–69 °C (white powder). ¹H NMR (400 MHz, CDCl₃) δ 2.43 (s, 3H, m-CH₃-Ph), 7.38–7.49 (m, 3H, Ar), 7.80 (d, 1H, Ar, *J* = 7.2 Hz), 7.85 (s, 1H, Ar), 8.26 (d, 1H, Ar, *J* = 8.0), 8.89 (d, 1H, Ar, *J* = 3.2). ¹³C NMR (100 MHz, CDCl₃) δ 21.3 (CH₃), 117.7 (C), 121.0 (CH), 122.8 (C), 128.1 (CH), 128.8 (CH), 129.7 (CH), 130.4 (C), 131.9 (CH), 134.4 (CH), 138.2 (C), 142.1 (C), 152.1 (CH), 159.1 (C), 165.0 (C). ESI-HRMS (*m/z*) calculated for [M + H]⁺ ion species C₁₅H₁₁F₃N₃O = 306,0849, found 306,0847. Anal. C₁₅H₁₀F₃N₃O (C, H, N).

Cyclopropyl(3-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-1-yl)methanone

(2b): Yield = 23%; oil. ¹H NMR (400 MHz, CDCl₃) δ 1.16–1.23 (m, 2H, CH₂ cC₃H₅), 1.38–1.44 (m, 2H, CH₂ cC₃H₅), 3.31–3.36 (m, 1H, COCH), 7.43–7.48 (m, 1H, Ar), 8.24 (d, 1H, Ar, *J* = 8.0), 8.85 (d, 1H, Ar, *J* = 2.8). ¹³C NMR (100 MHz, CDCl₃) δ 11.9 (CH₂), 13.6 (CH), 114.3 (C), 118.8 (C), 120.9 (CH), 121.9 (C), 129.7 (CH), 151.6 (C), 152.1 (CH), 172.5 (C). ESI-HRMS (*m/z*) calculated for [M + H]⁺ ion species C₁₁H₉F₃N₃O = 256,0692, found 256,0689. Anal. C₁₁H₈F₃N₃O (C, H, N).

Ethyl 1-(3-methylbenzoyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate (2l): Yield = 30%; mp = 185–187 °C (white powder). ¹H NMR (400 MHz, CDCl₃) δ 1.47 (t, 3H, OCH₂CH₃, *J* = 6.8), 2.44 (s, 3H, m-CH₃-Ph), 4.52 (q, 2H, OCH₂CH₃, *J* = 6.8), 7.40–7.48 (m, 3H, Ar), 7.83 (d, 1H, Ar, *J* = 7.2), 7.88 (s, 1H, Ar), 8.60 (d, 1H, Ar, *J* = 8.0), 8.83 (d, 1H, Ar, *J* = 4.0). ¹³C NMR (100 MHz, CDCl₃) δ 14.3 (CH₃), 21.3 (CH₃), 62.0 (CH₂), 108.0 (C), 121.1 (CH), 128.1 (CH), 128.9 (CH), 130.5 (C), 131.8 (CH), 132.1 (CH), 133.0 (C), 134.3 (CH), 136.7 (C), 138.1 (C), 151.4 (CH), 159.1 (C), 165.0 (C). ESI-HRMS (*m/z*) calculated for [M + H]⁺ ion species C₁₇H₁₆N₃O₃ = 310,1186, found 310,1183. Anal. C₁₇H₁₅N₃O₃ (C, H, N).

Isopropyl 1-(3-methylbenzoyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate (2m): Yield = 28%; mp = 192–194 °C (white powder). ¹H NMR (400 MHz, CDCl₃) δ 1.46 (d, 6H, CH(CH₃)₂, *J* = 6.0), 2.44 (s, 3H, m-CH₃-Ph), 5.43–5.48 (m, 1H, CH(CH₃)₂), 7.40–7.50 (m, 3H, Ar), 7.85 (d, 1H, Ar, *J* = 7.6), 7.90 (s, 1H, Ar), 8.57 (d, 1H, Ar, *J* = 8.0), 8.82 (d, 1H, Ar, *J* = 3.2). ¹³C NMR (100 MHz, CDCl₃) δ 21.3 (CH₃), 21.9 (CH₃), 70.0 (CH), 116.9 (C), 121.0 (CH), 128.3 (CH), 129.0 (CH), 131.8 (CH), 132.1 (CH), 134.2 (CH), 138.1 (C), 138.9 (C), 151.3 (CH), 153.2 (C), 160.8 (C), 166.7 (C). ESI-HRMS (*m/z*) calculated for [M + H]⁺ ion species C₁₈H₁₈N₃O₃ = 324,1343, found 324,1346. Anal. C₁₈H₁₇N₃O₃ (C, H, N).

m-Tolyl(3-(trifluoromethyl)-1H-pyrazolo[4,3-c]pyridin-1-yl)methanone (2n): Yield = 66%; mp = 80–81 °C (colorless solid). ¹H NMR (400 MHz, CDCl₃) δ 2.46 (s, 3H, m-CH₃-Ph), 7.41–7.49 (m, 2H, Ar), 7.92 (d, 2H, Ar, *J* = 6.4), 8.42 (d, 1H, Ar, *J* = 5.6), 8.80 (d, 1H,

Ar, $J = 6.0$), 9.29 (s, 1H, Ar). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 21.4 (CH_3), 110.4 (CH), 116.6 (C), 118.9 (C), 121.7 (C), 128.2 (CH), 128.8 (CH), 130.7 (C), 131.9 (CH), 134.5 (CH), 138.3 (C), 144.2 (CH), 145.0 (C), 148.4 (CH), 167.6 (C). ESI-HRMS (m/z) calculated for $[\text{M} + \text{H}]^+$ ion species $\text{C}_{15}\text{H}_{11}\text{F}_3\text{N}_3\text{O} = 306,0849$, found 306,0846. Anal. $\text{C}_{15}\text{H}_{10}\text{F}_3\text{N}_3\text{O}$ (C, H, N).

Cyclopropyl(3-(trifluoromethyl)-1H-pyrazolo[4,3-c]pyridin-1-yl)methanone (2o): Yield = 30%; mp = 93–94 °C (colorless solid). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 1.25–1.30 (m, 2H, CH_2 c C_3H_5), 1.39–1.44 (m, 2H, CH_2 c C_3H_5), 3.18–3.24 (m, 1H, COCH), 8.37 (d, 1H, Ar, $J = 6.0$), 8.75 (d, 1H, Ar, $J = 5.6$), 9.28 (s, 1H, Ar). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 12.0 (CH_2), 12.9 (CH), 110.1 (CH), 119.0 (C), 121.7 (C), 143.4 (C), 144.1 (CH), 148.3 (CH), 174.3 (C). ESI-HRMS (m/z) calculated for $[\text{M} + \text{H}]^+$ ion species $\text{C}_{11}\text{H}_9\text{F}_3\text{N}_3\text{O} = 256,0692$, found 256,0693. Anal. $\text{C}_{11}\text{H}_8\text{F}_3\text{N}_3\text{O}$ (C, H, N).

Ethyl 1-(3-methylbenzoyl)-1H-pyrazolo[4,3-c]pyridine-3-carboxylate (2r): Yield: 49%; mp = 87–89 °C (brown solid). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 1.48 (t, 3H, CH_3CH_2 , $J = 7.2$), 2.44 (s, 3H, m- CH_3 Ph), 4.55 (q, 2H, CH_2CH_2 , $J = 7.2$), 7.39–7.46 (m, 2H, Ar), 7.94 (d, 2H, Ar, $J = 7.2$), 8.36 (d, 1H, Ar, $J = 6.0$), 8.74 (d, 1H, Ar, $J = 5.6$), 9.58 (s, 1H, Ar). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 14.3 (CH_3), 21.4 (CH_3), 62.3 (CH_2), 110.1 (CH), 120.8 (C), 128.3 (CH), 129.0 (CH), 131.1 (C), 132.1 (CH), 134.4 (CH), 138.3 (C), 141.0 (C), 145.3 (C), 146.3 (CH), 147.8 (CH), 160.8 (C), 168.0 (C). ESI-HRMS (m/z) calculated for $[\text{M} + \text{H}]^+$ ion species $\text{C}_{17}\text{H}_{16}\text{N}_3\text{O}_3 = 310,1186$, found 310,1182. Anal. $\text{C}_{17}\text{H}_{15}\text{N}_3\text{O}_3$ (C, H, N).

Ethyl 1-(cyclopropanecarbonyl)-1H-pyrazolo[4,3-c]pyridine-3-carboxylate (2s): Yield: 44%; mp = 94–96 °C (white powder). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 1.23 (m, 2H, CH_2 c C_3H_5), 1.36 (m, 2H, CH_2 c C_3H_5), 1.50 (t, 3H, CH_2CH_3 , $J = 7.2$), 3.25–3.31 (m, 1H, CH c C_3H_5), 4.57 (q, 2H, CH_2CH_3 , $J = 7.2$), 8.25 (d, 1H, Ar, $J = 5.6$), 8.67 (d, 1H, Ar, $J = 5.6$), 9.52 (s, 1H, Ar). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 8.8 (CH), 12.2 (CH_2), 14.1 (CH_3), 60.9 (CH_2), 105.3 (C), 113.7 (CH), 126.2 (C), 136.7 (C), 143.1 (CH), 148.0 (CH), 160.6 (C), 172.3 (C). ESI-HRMS (m/z) calculated for $[\text{M} + \text{H}]^+$ ion species $\text{C}_{13}\text{H}_{14}\text{N}_3\text{O}_3 = 260,1030$, found 260,1030. Anal. $\text{C}_{13}\text{H}_{13}\text{N}_3\text{O}_3$ (C, H, N).

(3-Methyl-1H-pyrazolo[4,3-c]pyridin-1-yl)(m-tolyl)methanone (2t): Yield = 43%; mp = 104–105 °C (white powder). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 2.45 (s, 3H, m- CH_3 Ph), 2.67 (s, 3H, 3- CH_3), 7.39–7.45 (m, 2H, Ar), 7.89 (d, 2H, Ar, $J = 8.8$), 8.38 (d, 1H, Ar, $J = 6.6$), 8.70 (d, 1H, Ar, $J = 5.6$), 9.11 (s, 1H, Ar). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 12.4 (CH_3), 21.4 (CH_3), 102.9 (C), 110.3 (CH), 122.8 (C), 127.9 (CH), 128.4 (CH), 131.5 (CH), 132.4 (C), 133.5 (CH), 138.9 (C), 144.0 (CH), 144.8 (C), 147.9 (CH), 148.5 (C), 168.1 (C). ESI-HRMS (m/z) calculated for $[\text{M} + \text{H}]^+$ ion species $\text{C}_{15}\text{H}_{14}\text{N}_3\text{O} = 252,1131$, found 252,1129. Anal. $\text{C}_{15}\text{H}_{13}\text{N}_3\text{O}$ (C, H, N).

3.1.2. 1-Benzyl-1H-pyrazolo[3,4-b]pyridine-3-carbonitrile (2c)—To a suspension of the intermediate **1b**¹⁷ (0.42 mmol) in anhydrous CH_3CN (2 mL), 0.50 mmol of K_2CO_3 and 0.84 mmol of benzyl bromide were added. The mixture was stirred at reflux for 4 h. After evaporation of the solvent, ice-cold water (20 mL) was added and the precipitate was recovered by vacuum filtration. The final compound **2c** was purified by crystallization with

ethanol. Yield = 40%; mp = 110–112 °C (white powder). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 5.77 (s, 2H, $\text{CH}_2\text{-Ph}$), 7.42–7.49 (m, 6H, Ar), 8.18 (d, 1H, Ar, $J = 8.0$), 8.68 (d, 1H, Ar, $J = 2.8$). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 52.1 (CH_2), 105.0 (C), 112.9 (C), 117.1 (C), 119.6 (CH), 128.4 (CH), 128.4 (CH), 128.8 (CH), 135.3 (C), 150.6 (CH), 154.5 (C). IR = 2241 cm^{-1} (CN). ESI-HRMS (m/z) calculated for $[\text{M} + \text{H}]^+$ ion species $\text{C}_{14}\text{H}_{11}\text{N}_4 = 235,0978$, found 235,0981. Anal. $\text{C}_{14}\text{H}_{10}\text{N}_4$ (C, H, N).

3.1.3. 1-Benzoyl-1H-pyrazolo[3,4-b]pyridine-3-carbonitrile (2d)—To a solution of intermediate **1b**¹⁷ (1.04 mmol), 2.08 mmol of Benzoic acid and 1.56 mmol of HOBt in dry THF (5 mL), 2.08 mmol of triethylamine was added. The solution was brought to 0 °C, 1.56 mmol of *N,N'*-dicyclohexyl carbodiimide (DCC) was added and stirred at 0 °C for about 15'. The reaction mixture was stirred at room temperature for 48 h. After evaporation of the solvent, the crude compound was diluted in CH_2Cl_2 and first washed with 2 M Na_2CO_3 solution and then with brine. The organic phase was recovered, dried over sodium sulfate and evaporated under vacuum. The final compound **2d** was purified by crystallization with ethanol. Yield = 16%; mp = 208–210 °C (white powder). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.55–7.65 (m, 3H, Ar), 7.68 (d, 1H, Ar, $J = 6.0$), 8.03 (d, 2H, Ar, $J = 6.4$), 8.31 (d, 1H, Ar, $J = 6.8$), 8.93 (s, 1H, Ar). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 111.6 (C), 118.1 (C), 121.6 (CH), 122.3 (C), 128.4 (CH), 129.2 (CH), 131.1 (C), 131.6 (CH), 133.9 (CH), 152.7 (CH), 155.0 (C), 165.7 (C). IR = 2243 cm^{-1} (CN). ESI-HRMS (m/z) calculated for $[\text{M} + \text{H}]^+$ ion species $\text{C}_{14}\text{H}_9\text{N}_4\text{O} = 249,0771$, found 249,0769. Anal. $\text{C}_{14}\text{H}_8\text{N}_4\text{O}$ (C, H, N).

3.1.4. General procedure for compounds (2e-i, 2p, 2q)—To a suspension of the appropriate substrate **1b**¹⁷ or **1f**¹⁹ (0.86 mmol) in 10 mL of anhydrous THF, 1.72 mmol of sodium hydride and 1.03 mmol of the appropriate acyl/aroyl chloride were added. The mixture was stirred at room temperature overnight. The solvent was evaporated, cold water was added, and the mixture was neutralized with 2.5 N NaOH. The precipitate was recovered by vacuum filtration to obtain the final compounds **2e-i,p,q**, which were purified by crystallization with ethanol.

1-(3-Methylbenzoyl)-1H-pyrazolo[3,4-b]pyridine-3-carbonitrile (2e): Yield = 25%; mp = 210–213 °C (white powder). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 2.46 (s, 3H, *m-CH*₃-Ph), 7.41–7.55 (m, 3H, Ar), 7.77–7.82 (m, 2H, Ar), 8.31 (d, 1H, Ar, $J = 8.0$), 8.92 (d, 1H, Ar, $J = 2.8$). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 21.7 (CH_3), 105.0 (C), 110.5 (C), 114.2 (C), 119.6 (CH), 127.3 (CH), 128.4 (CH), 129.8 (CH), 130.4 (C), 130.7 (CH), 133.0 (C), 134.4 (CH), 138.9 (C), 150.2 (CH), 165.7 (C). IR = 2241 cm^{-1} (CN). ESI-HRMS (m/z) calculated for $[\text{M} + \text{H}]^+$ ion species $\text{C}_{15}\text{H}_{11}\text{N}_4\text{O} = 263,0927$, found 263,0926. Anal. $\text{C}_{15}\text{H}_{10}\text{N}_4\text{O}$ (C, H, N).

1-(4-Methylbenzoyl)-1H-pyrazolo[3,4-b]pyridine-3-carbonitrile (2f): Yield = 10%; mp = 140–143 °C (white powder). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 2.48 (s, 3H, *p-CH*₃-Ph), 7.37 (d, 2H, Ar, $J = 8.0$), 7.50–7.55 (m, 1H, Ar), 7.94 (d, 2H, Ar, $J = 8.0$), 8.30 (d, 1H, Ar, $J = 8.0$), 8.92 (d, 1H, Ar, $J = 3.6$). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 21.9 (CH_3), 105.0 (C), 111.7 (C), 118.0 (C), 121.5 (CH), 122.0 (C), 127.9 (CH), 129.2 (CH), 132.4 (CH), 145.3 (C), 151.9 (C), 152.6 (CH), 165.6 (C). IR = 2241 cm^{-1} (CN). ESI-HRMS (m/z) calculated for $[\text{M} + \text{H}]^+$ ion species $\text{C}_{15}\text{H}_{11}\text{N}_4\text{O} = 263,0927$, found 263,0927. Anal. $\text{C}_{15}\text{H}_{10}\text{N}_4\text{O}$ (C, H, N).

1-(Cyclopropanecarbonyl)-1H-pyrazolo[3,4-*b*]pyridine-3-carbonitrile (2g): Yield = 34%; mp = 147–149 °C (white powder). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 1.24–1.29 (m, 2H, CH_2 cC_3H_5), 1.45–1.50 (m, 2H, CH_2 cC_3H_5), 3.32–3.37 (m, 1H, *COCH*), 7.48–7.53 (m, 1H, Ar), 8.27 (d, 1H, Ar, $J = 8.0$), 8.88 (d, 1H, Ar, $J = 4.4$). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 12.3 (CH_2), 13.7 (CH), 105.0 (C), 110.4 (C), 114.1 (C), 121.4 (CH), 129.2 (CH), 133.0 (C), 152.5 (CH), 173.6 (C). IR = 2243 cm^{-1} (CN). ESI-HRMS (m/z) calculated for $[\text{M} + \text{H}]^+$ ion species $\text{C}_{11}\text{H}_9\text{N}_4\text{O} = 213,0771$, found 213,0772. Anal. $\text{C}_{11}\text{H}_8\text{N}_4\text{O}$ (C, H, N).

1-(Cyclopentanecarbonyl)-1H-pyrazolo[3,4-*b*]pyridine-3-carbonitrile (2h): Yield = 32%; mp = 123–125 °C (white powder). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 1.73–1.79 (m, 2H, CH_2 cC_5H_9), 1.80–1.85 (m, 2H, CH_2 cC_5H_9), 1.98–2.08 (m, 2H, CH_2 cC_5H_9), 2.10–2.16 (m, 2H, CH_2 cC_5H_9), 4.12 (quin, 1H, *COCH*, $J = 8.0$), 7.47–7.53 (m, 1H, Ar), 8.25 (d, 1H, Ar, $J = 8.0$), 8.89 (d, 1H, Ar, $J = 4.0$). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 25.8 (CH_2), 26.2 (CH_2), 30.0 (CH_2), 30.3 (CH_2), 44.2 (CH), 111.7 (C), 118.3 (C), 121.4 (CH), 122.2 (C), 129.1 (CH), 151.0 (C), 152.6 (CH), 174.4 (C). IR = 2243 cm^{-1} (CN). ESI-HRMS (m/z) calculated for $[\text{M} + \text{H}]^+$ ion species $\text{C}_{13}\text{H}_{13}\text{N}_4\text{O} = 241,1084$, found 241,108. Anal. $\text{C}_{13}\text{H}_{12}\text{N}_4\text{O}$ (C, H, N).

1-(Cyclohexanecarbonyl)-1H-pyrazolo[3,4-*b*]pyridine-3-carbonitrile (2i): Yield = 24%; mp = 124–127 °C (white powder). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 1.30–1.50 (m, 4H, $2 \times \text{CH}_2$ cC_6H_{11}), 1.73–1.78 (m, 2H, CH_2 cC_6H_{11}), 1.88 (d, 2H, CH_2 cC_6H_{11} , $J = 16.0$), 2.05 (d, 2H, CH_2 cC_6H_{11} , $J = 16.0$), 3.76 (t, 1H, *COCH*, $J = 8.0$), 7.47–7.52 (m, 1H, Ar), 8.25 (d, 1H, Ar, $J = 8.0$), 8.89 (d, 1H, Ar, $J = 4.0$). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 25.3 (CH_2), 25.6 (CH_2), 29.0 (CH_2), 43.9 (CH), 111.6 (C), 118.2 (C), 121.4 (CH), 122.2 (C), 129.1 (CH), 151.0 (C), 152.6 (CH), 171.1 (C). IR = 2243 cm^{-1} (CN). ESI-HRMS (m/z) calculated for $[\text{M} + \text{H}]^+$ ion species $\text{C}_{14}\text{H}_{15}\text{N}_4\text{O} = 255,1240$, found 255,1243. Anal. $\text{C}_{14}\text{H}_{14}\text{N}_4\text{O}$ (C, H, N).

1-(3-Methylbenzoyl)-1H-pyrazolo[4,3-*c*]pyridine-3-carbonitrile (2p): Yield = 47%; mp = 192–194 °C (colorless solid). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 2.48 (s, 3H, *m-CH}_3\text{-Ph}*), 7.46 (t, 1H, Ar, $J = 7.6$), 7.52 (d, 1H, Ar, $J = 7.2$), 7.88 (d, 2H, Ar, $J = 6.8$), 8.45 (d, 1H, Ar, $J = 6.0$), 8.84 (d, 1H, Ar, $J = 6.0$), 9.34 (s, 1H, Ar). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 21.4 (CH_3), 110.5 (CH), 111.2 (C), 122.1 (C), 124.0 (C), 128.4 (CH), 128.8 (CH), 130.3 (C), 131.9 (CH), 134.9 (CH), 138.5 (C), 143.7 (CH), 144.2 (C), 148.8 (CH), 167.3 (C). IR = 2241 cm^{-1} (CN). ESI-HRMS (m/z) calculated for $[\text{M} + \text{H}]^+$ ion species $\text{C}_{15}\text{H}_{11}\text{N}_4\text{O} = 263,0927$, found 263,0926. Anal. $\text{C}_{15}\text{H}_{10}\text{N}_4\text{O}$ (C, H, N).

1-(Cyclopropanecarbonyl)-1H-pyrazolo[4,3-*c*]pyridine-3-carbonitrile (2q): Yield = 44%; mp = 152–154 °C (white powder). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 1.30–1.35 (m, 2H, CH_2 cC_3H_5), 1.42–1.47 (m, 2H, CH_2 cC_3H_5), 3.14–3.20 (m, 1H, *COCH*), 8.41 (d, 1H, Ar, $J = 6.0$), 8.78 (d, 1H, Ar, $J = 5.6$), 9.34 (s, 1H, Ar). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 12.4 (CH_2), 12.9 (CH), 110.2 (CH), 111.2 (C), 122.2 (C), 123.7 (C), 142.6 (C), 143.7 (CH), 148.8 (CH), 173.9 (C). IR = 2243 cm^{-1} (CN). ESI-HRMS (m/z) calculated for $[\text{M} + \text{H}]^+$ ion species $\text{C}_{11}\text{H}_9\text{N}_4\text{O} = 213,0771$, found 213,0768. Anal. $\text{C}_{11}\text{H}_8\text{N}_4\text{O}$ (C, H, N).

3.1.5. Cyclopropyl(3-nitro-1H-pyrazolo[3,4-*b*]pyridin-1-yl)methanone (4)—
Compound 4 was obtained using the general procedure followed for compounds 2e-i, 2p,

2q, but starting from intermediate **3**.²² The compound **4** was purified by crystallization with ethanol. Yield = 30%; mp = 137–139 °C (white powder). ¹H NMR (400 MHz, CDCl₃) δ 1.28–1.33 (m, 2H, CH₂ cC₃H₅), 1.47–1.52 (m, 2H, CH₂ cC₃H₅), 3.29–3.35 (m, 1H, COCH), 7.58–7.63 (m, 1H, Ar), 8.68 (dd, 1H, Ar, *J*₁ = 1.4 and *J*₂ = 8.0), 8.90 (d, 1H, Ar, *J* = 4.4). ¹³C NMR (100 MHz, CDCl₃) δ 12.6 (CH₂), 13.8 (CH), 110.6 (C), 122.7 (CH), 131.2 (CH), 142.6 (C), 151.8 (C), 152.9 (CH), 172.2 (C). ESI-HRMS (*m/z*) calculated for [M + H]⁺ ion species C₁₀H₉N₄O₃ = 233,0669, found 233,0671. Anal. C₁₀H₈N₄O₃ (C, H, N).

3.1.6. General procedure for compounds (6–8)—1H-pyrazolo[3,4-*b*]pyridin-3-amine (**5**²²) (1.27 mmol) was dissolved in 8 mL of DMF and triethylamine (12.67 mmol). The appropriate acyl/aroyl chloride (1.33 mmol) dissolved in 2.5 mL dry 1,4-dioxane was added dropwise to the reaction mixture at 10 °C, then left stirring at 50 °C for 4 h. Ice water was added to the reaction mixture, and the product was extracted with ethyl acetate (3 × 15 mL), dried over sodium sulfate, and evaporated under vacuum. The crude compounds **6–8** were purified by flash column chromatography using dichloromethane/methanol 95:5 as eluent. Finally, all compounds were crystallized from ethanol, and melting points were performed after crystallization.

(3-Amino-1H-pyrazolo[3,4-*b*]pyridin-1-yl)(cyclopropyl)methanone (6): Yield = 5%; oil. ¹H NMR (400 MHz, DMSO-*d*₆) δ 0.81–0.88 (m, 2H, CH₂ cC₃H₅), 1.19–1.25 (m, 2H, CH₂ cC₃H₅), 3.50–3.57 (m, 1H, COCH), 6.53 (exch br s, 2H, NH₂), 7.33–7.38 (m, 1H, Ar), 8.30 (d, 1H, Ar, *J* = 6.0), 8.57 (s, 1H, Ar). ¹³C NMR (100 MHz, DMSO-*d*₆) δ 8.7 (CH), 12.2 (CH₂), 106.5 (C), 114.1 (CH), 126.7 (CH), 142.9 (C), 148.0 (CH), 155.3 (C), 174.0 (C). ESI-HRMS (*m/z*) calculated for [M + H]⁺ ion species C₁₀H₁₁N₄O = 203,0927, found 203,0925. Anal. C₁₀H₁₀N₄O (C, H, N).

N-(1-(Cyclopropanecarbonyl)-1H-pyrazolo[3,4-*b*]pyridin-3-yl)cyclopropanecarboxamide (7): Yield = 15%;

mp = 222–225 °C (white powder). ¹H NMR (400 MHz, CDCl₃) δ 0.93–1.00 (m, 2H, CH₂ cC₃H₅), 1.13–1.19 (m, 4H, 2 × CH₂ cC₃H₅), 1.33–1.39 (m, 2H, CH₂ cC₃H₅), 1.81–1.87 (m, 1H, NHCOCH), 3.60–3.65 (m, 1H, *N*-COCH), 7.25–7.30 (m, 1H, Ar), 8.65 (d, 1H, Ar, *J* = 1.2), 8.75 (d, 1H, Ar, *J* = 7.6), 9.41 (exch br s, 1H, NH). ¹³C NMR (100 MHz, CDCl₃) δ 25.3 (CH₂), 25.6 (CH₂), 28.9 (CH₂), 43.2 (CH), 111.6 (C), 118.2 (C), 121.4 (CH), 122.2 (C), 129.1 (CH), 151.0 (C), 152.6 (CH), 174.1 (C). ESI-HRMS (*m/z*) calculated for [M + H]⁺ ion species C₁₄H₁₅N₄O₂ = 271,1190, found 271,1193. Anal. C₁₄H₁₄N₄O₂ (C, H, N).

3-Methyl-N-(1H-pyrazolo[3,4-*b*]pyridin-3-yl)benzamide (8): Yield = 15%; mp = 205–208 °C (white powder). ¹H NMR (400 MHz, DMSO-*d*₆) δ 2.37 (s, 3H, m-CH₃-Ph), 7.13–7.18 (m, 1H, Ar), 7.40–7.45 (m, 2H, Ar), 7.80–7.85 (m, 2H, Ar), 8.27 (d, 1H, Ar, *J* = 6.8), 8.49 (s, 1H, Ar), 10.95 (exch br s, 1H, NHCO), 13.31 (exch br s, 1H, NH). ¹³C NMR (100 MHz, DMSO-*d*₆) δ 20.9 (CH₃), 91.5 (C), 114.0 (CH), 124.5 (CH), 126.7 (CH), 128.7 (CH), 131.4 (CH), 132.4 (CH), 134.1 (C), 138.5 (C), 148.0 (CH), 150.7 (C), 154.0 (C), 164.7 (C). ESI-HRMS (*m/z*) calculated for [M + H]⁺ ion species C₁₄H₁₃N₄O = 253,1084, found 253,1082. Anal. C₁₄H₁₂N₄O (C, H, N).

3.1.7. N-(1-Acetyl-1H-pyrazolo[3,4-b]pyridin-3-yl)-3-methylbenzamide (9)—

Compound **9** was obtained following the general procedure performed for compounds **2a,b**, **2l-o** and **2r-t** but starting from intermediate **8** and using acetyl chloride as reagent. The crude product was purified by flash column chromatography using cyclohexane/ethyl acetate 1:3 as eluent. Yield = 11%; oil. $^1\text{H NMR}$ (400 MHz, $\text{CDCl}_3 + \text{D}_2\text{O}$) δ 2.43 (s, 3H, m- CH_3 -Ph), 2.91 (s, 3H, NHCOCH_3), 7.30–7.35 (m, 1H, Ar), 7.40–7.45 (m, 2H, Ar), 7.76 (d, 1H, Ar, $J = 6.0$), 7.79 (s, 1H, Ar), 8.69 (d, 1H, Ar, $J = 3.2$), 8.84 (d, 1H, Ar, $J = 8.4$). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 20.9 (CH_3), 21.5 (CH_3), 106.4 (C), 113.9 (CH), 124.5 (CH), 126.7 (CH), 128.7 (CH), 131.4 (CH), 132.0 (C), 132.5 (CH), 134.1 (C), 138.5 (C), 148.0 (CH), 155.4 (C), 164.7 (C), 169.2 (C). ESI-HRMS (m/z) calculated for $[\text{M} + \text{H}]^+$ ion species $\text{C}_{16}\text{H}_{15}\text{N}_4\text{O}_2 = 295,1190$, found 295,1184. Anal. $\text{C}_{16}\text{H}_{14}\text{N}_4\text{O}_2$ (C, H, N).

3.1.8. General procedure for compounds (11a,b)—A mixture of the appropriate 1H-pyrrolo[2,3-*b*]pyridine-3-carbaldehyde **10a**²⁴ or **10b**²⁴ (0.78 mmol) and hydroxylamine hydrochloride (2.35 mmol) in 2 mL of water was heated at 60 °C for 30 min, and NaHCO_3 (2.35 mmol) was added to the reaction mixture, which was finally left under reflux for 4 h. The reaction mixture was cooled to room temperature, the solid obtained was filtered, washed with the excess of ice-cold water and dried. The crude products were recrystallized from hexane to obtain the pure compounds.

(E)-1H-Pyrrolo[3,2-*b*]pyridine-3-carbaldehyde oxime (11a): Yield = 65%; mp = 221–222 °C (colorless solid). $^1\text{H NMR}$ (400 MHz, $\text{DMSO-}d_6$) δ 7.14–7.19 (m, 1H, Ar), 7.81 (d, 1H, Ar, $J = 8.0$), 7.84 (s, 1H, $\text{CH} = \text{N-OH}$), 8.38 (d, 1H, Ar, $J = 4.4$), 8.43 (s, 1H, Ar), 11.31 (exch br s, 1H, $\text{CH} = \text{N-OH}$), 11.73 (exch br s, 1H, NH). ESI-HRMS (m/z) calculated for $[\text{M} + \text{H}]^+$ ion species $\text{C}_8\text{H}_8\text{N}_3\text{O} = 162,0662$, found 162,0659. Anal. $\text{C}_8\text{H}_7\text{N}_3\text{O}$ (C, H, N).

(E)-1H-Pyrrolo[3,2-*c*]pyridine-3-carbaldehyde oxime (11b): Yield = 91%; mp = 227–228 °C (colorless solid). $^1\text{H NMR}$ (400 MHz, $\text{DMSO-}d_6$) δ 7.39 (d, 1H, Ar, $J = 5.6$), 7.86 (s, 1H, $\text{CH} = \text{N-OH}$), 8.21 (d, 2H, Ar, $J = 7.2$), 9.15 (s, 1H, Ar), 11.38 (exch br s, 1H, $\text{CH} = \text{N-OH}$), 11.88 (exch br s, 1H, NH). ESI-HRMS (m/z) calculated for $[\text{M} + \text{H}]^+$ ion species $\text{C}_8\text{H}_8\text{N}_3\text{O} = 162,0662$, found 162,0665. Anal. $\text{C}_8\text{H}_7\text{N}_3\text{O}$ (C, H, N).

3.1.9. General procedure for compounds (12a,b)—A mixture of intermediate **11a** or **11b** (0.92 mmol) and 4 mL of POCl_3 was stirred at reflux for 2 h. After cooling, ice-cold water (20 mL) was slowly added, and the precipitate was filtered under vacuum and washed with abundant cold water to obtain the desired compounds. Finally, both compounds were crystallized from ethanol, and melting points were performed after crystallization.

1H-Pyrrolo[3,2-*b*]pyridine-3-carbonitrile (12a): Yield = 86%; mp > 300 °C (white powder). $^1\text{H NMR}$ (400 MHz, $\text{DMSO-}d_6$) δ 7.25–7.30 (m, 1H, Ar), 7.93 (d, 1H, Ar, $J = 7.2$), 8.46 (d, 2H, Ar, $J = 3.2$), 12.36 (exch br s, 1H, NH). IR = 2240 cm^{-1} (CN). ESI-HRMS (m/z) calculated for $[\text{M} + \text{H}]^+$ ion species $\text{C}_8\text{H}_6\text{N}_3 = 144,0556$, found 144,0559. Anal. $\text{C}_8\text{H}_5\text{N}_3$ (C, H, N).

1H-Pyrrolo[3,2-*c*]pyridine-3-carbonitrile (12b): Yield = 46%; mp = 262–263 °C dec. (white powder). $^1\text{H NMR}$ (400 MHz, $\text{DMSO-}d_6$) δ 7.53 (d, 1H, Ar, $J = 5.2$), 8.34 (d, 1H, Ar,

$J = 5.6$), 8.37 (s, 1H, Ar), 8.92 (s, 1H, Ar), 12.51 (exch br s, 1H, NH). IR = 2240 cm^{-1} (CN). ESI-HRMS (m/z) calculated for $[M + H]^+$ ion species $\text{C}_8\text{H}_6\text{N}_3 = 144,0556$, found 144,0555. Anal. $\text{C}_8\text{H}_5\text{N}_3$ (C, H, N).

3.1.10. General procedure for compounds (13a-f)—Compounds **13a-f** were obtained using the general procedure followed for compounds **2a,b,l-o,r-t** but starting from intermediate **12a-c** (**12c**²⁶). The crude products were purified by crystallization from ethanol (**13a-c** and **13f**) or by flash column chromatography using cyclohexane/ethyl acetate 1:1 (**13d,e**) as eluent. Finally, all compounds were crystallized from ethanol, and melting points were performed after crystallization.

1-(3-Methylbenzoyl)-1H-pyrrolo[3,2-*b*]pyridine-3-carbonitrile (13a): Yield = 55%; mp = 190–191 °C (colorless solid). ¹H NMR (400 MHz, CDCl_3) δ 2.48 (s, 3H, *m*- CH_3 -Ph), 7.41–7.46 (m, 1H, Ar), 7.49–7.56 (m, 4H, Ar), 8.09 (s, 1H, Ar), 8.61 (d, 1H, Ar, $J = 8.0$), 8.74 (d, 1H, Ar, $J = 4.8$). ¹³C NMR (100 MHz, CDCl_3) δ 21.4 (CH_3), 94.8 (C), 112.5 (C), 121.3 (CH), 124.3 (CH), 126.7 (CH), 128.9 (C), 129.1 (CH), 130.0 (CH), 131.6 (C), 134.4 (CH), 136.8 (CH), 139.5 (C), 145.7 (C), 148.2 (CH), 167.8 (C). IR = 1726 cm^{-1} (CO), 2222 cm^{-1} (CN). ESI-HRMS (m/z) calculated for $[M + H]^+$ ion species $\text{C}_{16}\text{H}_{12}\text{N}_3\text{O} = 262,0975$, found 262,0970. Anal. $\text{C}_{16}\text{H}_{11}\text{N}_3\text{O}$ (C, H, N).

1-(Cyclopropanecarbonyl)-1H-pyrrolo[3,2-*b*]pyridine-3-carbonitrile (13b): Yield = 34%; mp = 134–135 °C (brown solid). ¹H NMR (400 MHz, CDCl_3) δ 1.22–1.27 (m, 2H, CH_2 cC_3H_5), 1.38–1.43 (m, 2H, CH_2 cC_3H_5), 2.24–2.29 (m, 1H, *COCH*), 7.37–7.42 (m, 1H, Ar), 8.47 (s, 1H, Ar), 8.67 (d, 2H, Ar, $J = 8.4$). ¹³C NMR (100 MHz, CDCl_3) δ 11.2 (CH_2), 13.7 (CH), 95.2 (C), 112.6 (C), 121.3 (CH), 124.6 (CH), 128.5 (C), 134.2 (CH), 145.4 (C), 147.9 (CH), 171.7 (C). IR = 1718 cm^{-1} (CO), 2231 cm^{-1} (CN). ESI-HRMS (m/z) calculated for $[M + H]^+$ ion species $\text{C}_{12}\text{H}_{10}\text{N}_3\text{O} = 212,0818$, found 212,0819. Anal. $\text{C}_{12}\text{H}_9\text{N}_3\text{O}$ (C, H, N).

1-(3-Methylbenzoyl)-1H-pyrrolo[3,2-*c*]pyridine-3-carbonitrile (13c): Yield = 40%; mp = 180–181 °C (colorless solid). ¹H NMR (400 MHz, CDCl_3) δ 2.48 (s, 3H, *m*- CH_3 -Ph), 7.50–7.57 (m, 4H, Ar), 7.99 (s, 1H, Ar), 8.23 (d, 1H, Ar, $J = 4.8$), 8.69 (d, 1H, Ar, $J = 4.8$), 9.16 (s, 1H, Ar). ¹³C NMR (100 MHz, CDCl_3) δ 21.4 (CH_3), 92.1 (C), 111.2 (CH), 112.6 (C), 126.7 (CH), 129.2 (CH), 130.0 (CH), 131.5 (C), 134.7 (CH), 135.8 (CH), 139.6 (C), 139.9 (C), 142.4 (CH), 145.7 (CH), 167.6 (C). IR = 1707 cm^{-1} (CO), 2233 cm^{-1} (CN). ESI-HRMS (m/z) calculated for $[M + H]^+$ ion species $\text{C}_{16}\text{H}_{12}\text{N}_3\text{O} = 262,0975$, found 262,0973. Anal. $\text{C}_{16}\text{H}_{11}\text{N}_3\text{O}$ (C, H, N).

1-(Cyclopropanecarbonyl)-1H-pyrrolo[3,2-*c*]pyridine-3-carbonitrile (13d): Yield = 24%; mp = 139–140 °C (brown solid). ¹H NMR (400 MHz, CDCl_3) δ 1.25–1.30 (m, 2H, CH_2 cC_3H_5), 1.41–1.46 (m, 2H, CH_2 cC_3H_5), 2.23–2.28 (m, 1H, *COCH*), 8.32 (d, 2H, Ar, $J = 4.8$), 8.56 (s, 1H, Ar), 9.12 (s, 1H, Ar). ¹³C NMR (100 MHz, CDCl_3) δ 11.4 (CH_2), 14.3 (CH), 92.6 (C), 111.4 (CH), 112.7 (C), 124.1 (C), 133.2 (CH), 139.2 (C), 142.5 (CH), 146.1 (CH), 171.6 (C). IR = 1710 cm^{-1} (CO), 2232 cm^{-1} (CN). ESI-HRMS (m/z) calculated for $[M + H]^+$ ion species $\text{C}_{12}\text{H}_{10}\text{N}_3\text{O} = 212,0818$, found 212,0817. Anal. $\text{C}_{12}\text{H}_9\text{N}_3\text{O}$ (C, H, N).

1-(3-Methylbenzoyl)-1H-pyrrolo[2,3-c]pyridine-3-carbonitrile (13e): Yield = 14%; mp = 157–159 °C (colorless solid). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 2.51 (s, 3H, m- CH_3 -Ph), 7.51–7.62 (m, 4H, Ar), 8.08 (s, 1H, Ar), 8.35 (d, 1H, Ar, $J = 12.0$), 8.71 (d, 1H, Ar, $J = 5.6$), 9.79 (s, 1H, Ar). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 21.4 (CH_3), 92.7 (C), 112.8 (C), 114.2 (CH), 126.7 (CH), 129.1 (CH), 130.0 (CH), 131.6 (C), 132.1 (C), 133.2 (C), 134.0 (CH), 137.1 (CH), 138.9 (CH), 139.6 (C), 144.3 (CH), 167.7 (C). IR = 1709 cm^{-1} (CO), 2231 cm^{-1} (CN). ESI-HRMS (m/z) calculated for $[\text{M} + \text{H}]^+$ ion species $\text{C}_{16}\text{H}_{12}\text{N}_3\text{O} = 262,0975$, found 262,0972. Anal. $\text{C}_{16}\text{H}_{11}\text{N}_3\text{O}$ (C, H, N).

1-(Cyclopropanecarbonyl)-1H-pyrrolo[2,3-c]pyridine-3-carbonitrile (13f): Yield = 61%; mp = 188–189 °C (brown solid). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 1.31–1.36 (m, 2H, CH_2 c C_3H_5), 1.48–1.53 (m, 2H, CH_2 c C_3H_5), 2.26–2.31 (m, 1H, COCH), 7.87 (d, 1H, Ar, $J = 5.2$), 8.54 (s, 1H, Ar), 8.64 (d, 1H, Ar, $J = 5.2$), 9.79 (s, 1H, Ar). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 11.4 (CH_2), 14.1 (CH), 92.9 (C), 112.9 (C), 114.0 (CH), 131.6 (C), 133.7 (C), 134.6 (CH), 139.1 (CH), 144.0 (CH), 171.2 (C). IR = 1722 cm^{-1} (CO), 2233 cm^{-1} (CN). ESI-HRMS (m/z) calculated for $[\text{M} + \text{H}]^+$ ion species $\text{C}_{12}\text{H}_{10}\text{N}_3\text{O} = 212,0818$, found 212,0820. Anal. $\text{C}_{12}\text{H}_9\text{N}_3\text{O}$ (C, H, N).

3.1.11. General procedure for compounds (15a,b and 19a,b)—Compounds **15a,b** and **19a,b** were obtained using the general procedures followed for compounds **2a,b,l-o,r-t** but starting from intermediate **14**²⁷ for **15a,b** or **18** for **19a,b**. The final compounds were purified by flash column chromatography using dichloromethane/methanol 98:2 (**15a** and **19a**) or cyclohexane/ethyl acetate 3:1 (**15b** and **19b**) as eluents. Finally, all compounds were crystallized from ethanol, and melting points were performed after crystallization.

(5H-Pyrrolo[2,3-b]pyrazin-5-yl)(m-tolyl)methanone (15a): Yield: 19%; mp = 108–110 °C (white powder). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 2.40 (s, 3H, m- CH_3 -Ph), 6.87 (d, 1H, Ar, $J = 4.0$ Hz), 7.40 (t, 1H, Ar, $J = 7.6$), 7.49 (d, 1H, Ar, $J = 7.6$), 7.55 (d, 1H, Ar, $J = 7.6$), 7.60 (s, 1H, Ar), 8.13 (d, 1H, Ar, $J = 4.0$), 8.24 (d, 1H, Ar, $J = 2.4$), 8.62 (d, 1H, Ar, $J = 2.4$). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 21.2 (CH_3), 100.8 (CH), 106.7 (CH), 127.8 (CH), 128.7 (CH), 130.5 (C), 131.6 (CH), 133.5 (C), 134.3 (CH), 137.2 (CH), 138.3 (C), 138.5 (CH), 141.7 (C), 167.8 (C). ESI-HRMS (m/z) calculated for $[\text{M} + \text{H}]^+$ ion species $\text{C}_{14}\text{H}_{12}\text{N}_3\text{O} = 238,0975$, found 238,0971. Anal. $\text{C}_{14}\text{H}_{11}\text{N}_3\text{O}$ (C,H,N).

Cyclopropyl(5H-pyrrolo[2,3-b]pyrazin-5-yl)methanone (15b): Yield: 25%; mp = 117–119 °C (white powder). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 1.21–1.29 (m, 2H, CH_2 c C_3H_5), 1.37–1.42 (m, 2H, CH_2 c C_3H_5), 4.00 (ept, 1H, CH c C_3H_5 , $J_1 = 3.6$ and $J_2 = 4.4$), 6.85 (d, 1H, Ar, $J = 4.0$), 8.33 (m, 2H, Ar), 8.53 (d, 1H, Ar, $J = 2.4$). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 11.8 (CH_2), 14.6 (CH), 106.3 (CH), 130.0 (CH), 137.4 (CH), 140.5 (CH), 141.7 (C), 143.1 (C), 172.7 (C) ESI-HRMS (m/z) calculated for $[\text{M} + \text{H}]^+$ ion species $\text{C}_{10}\text{H}_{10}\text{N}_3\text{O} = 188,0818$, found 188,0817. Anal. $\text{C}_{10}\text{H}_9\text{N}_3\text{O}$ (C,H,N).

5-(3-Methylbenzoyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbonitrile(19a): Yield: 4%; mp = 140–141 °C (white powder). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 2.45 (s, 3H, m- CH_3 -Ph), 7.38–7.48 (m, 1H, Ar), 7.53–7.58 (m, 2H, Ar), 7.65 (s, 1H, Ar), 8.42 (d, 1H, Ar, $J = 2.4$), 8.52 (s, 1H, Ar), 8.68 (d, 1H, Ar, $J = 2.4$). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 20.9 (CH_3),

83.6 (C), 113.6 (C), 119.4 (CH), 120.7 (C), 128.1 (CH), 129.2 (CH), 130.1 (CH), 130.5 (C), 134.8 (CH), 138.9 (C), 144.3 (CH), 145.8 (CH), 147.8 (C), 167.8 (C). ESI-HRMS (m/z) calculated for $[M + H]^+$ ion species $C_{15}H_{11}N_4O = 263,0927$, found 263,0924. Anal. $C_{15}H_{10}N_4O$ (C,H,N).

5-(Cyclopropanecarbonyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbonitrile (19b): Yield: 20%; mp = 158–159 °C (white powder). 1H NMR (400 MHz, $CDCl_3$) δ 1.33 (m, 2H, CH_2 c C_3H_5), 1.46 (m, 2H, CH_2 c C_3H_5), 3.93 (m, 1H, CH c C_3H_5), 8.49 (s, 1H, Ar), 8.69 (s, 1H, Ar), 8.75 (s, 1H, Ar). ^{13}C NMR (100 MHz, $CDCl_3$) δ 11.4 (CH), 12.6 (CH_2), 83.7 (C), 113.5 (C), 119.5 (CH), 120.7 (C), 144.2 (CH), 145.9 (CH), 147.9 (C), 172.8 (C). ESI-HRMS (m/z) calculated for $[M + H]^+$ ion species $C_{11}H_9N_4O = 213,0771$, found 213,0774. Anal. $C_{11}H_8N_4O$ (C,H,N).

3.1.12. 5H-Pyrrolo[2,3-b]pyrazine-7-carbaldehyde oxime (17)—Compound **17** was obtained using the general procedure followed for compounds **11a,b** but starting from intermediate **16**.²⁷ The desired compound was purified by crystallization from ethanol. Yield: 90%; mp = 239–240 °C dec. (colorless solid). 1H NMR (400 MHz, $DMSO-d_6$) δ 8.12 (s, 1H, Ar), 8.27 (s, 2H, Ar), 8.43 (s, 1H, $CH = N$), 10.85 (exch br s, 1H, OH), 12.38 (exch br s, 1H, NH). ESI-HRMS (m/z) calculated for $[M + H]^+$ ion species $C_7H_7N_4O = 163,0614$, found 163,0617. Anal. $C_7H_6N_4O$ (C,H,N).

3.1.13. 5H-Pyrrolo[2,3-b]pyrazine-7-carbonitrile (18)—Compound **18** was obtained using the general procedure followed for compounds **12a,b** but starting from intermediate **17**. The desired compound was purified by flash column chromatography using dichloromethane/methanol 9:1 as eluent. Yield: 20%; mp > 300 °C (white powder). 1H NMR (400 MHz, $DMSO-d_6$) δ 8.44 (d, 1H, Ar, $J = 2.4$), 8.56 (d, 1H, Ar, $J = 2.4$), 8.75 (s, 1H, Ar), 13.20 (exch br s, 1H, NH). IR = 2227 cm^{-1} (CN), 3390 cm^{-1} (NH). ESI-HRMS (m/z) calculated for $[M + H]^+$ ion species $C_7H_5N_4 = 145,0509$, found 145,0508. Anal. $C_7H_4N_4$ (C,H,N).

3.1.14. Ethyl 2-tert-butyl-3-chloro-7-methylpyrazolo[1,5-a]pyrimidine-6-carboxylate (20c)—To a solution of the pyrazolo[1,5-a]pyrimidine **20b**²⁸ (0.50 mmol) and dichloromethane (10 mL), *N*-chlorosuccinimide (NCS) (100 mg) and a catalytic amount of benzoyl peroxide were added. The reaction mixture was stirred under reflux for 12 h. The solution was evaporated, and the crude product was recrystallized from diisopropyl ether. Yield = 70%; mp = 59–60 °C (white powder). 1H NMR (400 MHz, $DMSO-d_6$) δ 1.41 (s, 9H, C-(CH_3)₃), 1.44 (t, 3H, OCH_2CH_3 , $J = 7.2$), 3.10 (s, 3H, CH_3), 4.41 (q, 2H, OCH_2CH_3 , $J = 7.2$), 8.87 (s, 1H, Ar). ESI-HRMS (m/z) calculated for $[M + H]^+$ ion species $C_{14}H_{18}ClN_3O_2 = 296,1160$, found 296,1155. Anal. $C_{14}H_{18}ClN_3O_2$ (C,H,N).

3.1.15. 2-(tert-Butyl)-3-chloro-7-methylpyrazolo[1,5-a]pyrimidine-6-carboxylic acid (21c)—To a suspension of ethyl 2-(tert-butyl)-3-chloro-7-methylpyrazolo [1,5-a]pyrimidine-6-carboxylate **20c** (1.01 mmol) in 5 mL of sodium hydroxide 40%, the minimum volume of ethanol needed to solubilize the solid was added. The reaction was kept stirring under reflux for 1 h. The mixture was cooled to 0 °C and acidified with

hydrochloride acid 6 N to pH 2. The solid was filtered under vacuum and crystallized using ethanol as solvent to obtain the pure product. Yield = 96%; mp = 269–270 °C (white powder). ¹H NMR (400 MHz, DMSO-*d*₆) δ 1.45 (s, 9H, C-(CH₃)₃), 3.04 (s, 3H, CH₃), 8.85 (s, 1H, Ar). ESI-HRMS (*m/z*) calculated for [M + H]⁺ ion species C₁₂H₁₅ClN₃O₂ = 268,0847, found 268,0845. Anal. C₁₂H₁₄ClN₃O₂ (C,H,N).

3.1.16. General procedure for compounds (22a-g)—To a solution of the appropriate acid of type **21**^{30–32} (0.373 mmol) in 3 mL of anhydrous dichloromethane, first 1.87 mmol of trichloro acetonitrile, and then, after 5 min, 0.71 mmol of triphenylphosphine were added, and the suspension was stirred at room temperature. After 4 h, 0.373 mmol of *m*-anisidine or 3-methoxybenzylamine and 1.12 mmol of triethylamine were added to the mixture, which was then left for other 12 h stirring at room temperature. The solvent was evaporated, cold water was added, and the mixture was extracted with CH₂Cl₂ (3 × 15 mL). The organic solvent was dried over sodium sulfate and evaporated under vacuum. The final compounds **22a-g** were purified by flash column chromatography using cyclohexane/ethyl acetate 1:1 (for **22a, g,h**) or 2:1 (for **22d,f**), petroleum ether/ethyl acetate 5:2 (for **22b,e**), dichloromethane/methanol 98:2 (for **22c**) as eluents. Finally, all compounds were crystallized from ethanol, and melting points were performed after crystallization.

N-(3-Methoxyphenyl)-2,7-dimethylpyrazolo[1,5-*a*]pyrimidine-6-carboxamide (22a).: Yield = 19%; mp = 128–129 °C (brown solid). ¹H NMR (400 MHz, CDCl₃) δ 2.49 (s, 3H, CH₃), 2.90 (s, 3H, CH₃), 3.79 (s, 3H, OCH₃), 6.40 (s, 1H, Ar), 6.71 (dd, 1H, Ar, *J*₁ = 2.4 and *J*₂ = 8.8), 7.11 (d, 1H, Ar, *J* = 7.6), 7.23 (t, 1H, Ar, *J* = 8.2), 7.36 (s, 1H, Ar), 8.44 (s, 1H, Ar), 8.45 (exch br s, 1H, NH). ¹³C NMR (100 MHz, CDCl₃) δ 14.8 (CH₃), 14.9 (CH₃), 55.4 (CH₃), 97.2 (CH), 106.0 (CH), 110.9 (CH), 112.3 (CH), 115.9 (C), 129.9 (CH), 138.8 (C), 146.3 (CH), 147.1 (C), 148.6 (C), 156.9 (C), 160.3 (C), 163.6 (C). ESI-HRMS (*m/z*) calculated for [M + H]⁺ ion species C₁₆H₁₇N₄O₂ = 297,1346, found 297,1351. Anal. C₁₆H₁₆N₄O₂ (C,H,N).

2-(tert-Butyl)-N-(3-methoxyphenyl)-7-methylpyrazolo[1,5-*a*]pyrimidine-6-carboxamide (22b).: Yield = 14%; mp = 114–115 °C (brown solid). ¹H NMR (400 MHz, CDCl₃) δ 1.40 (s, 9H, C-(CH₃)₃), 2.99 (s, 3H, CH₃), 3.79 (s, 3H, OCH₃), 6.54 (s, 1H, Ar), 6.72 (dd, 1H, Ar, *J*₁ = 2.0 and *J*₂ = 8.2), 7.10 (d, 1H, Ar, *J* = 7.6), 7.25 (t, 1H, Ar, *J* = 8.2), 7.39 (exch br s, 1H, NH), 8.09 (s, 1H, Ar), 8.54 (s, 1H, Ar). ¹³C NMR (100 MHz, CDCl₃) δ 14.8 (CH₃), 30.3 (CH₃), 33.1 (C), 55.4 (CH₃), 93.8 (CH), 106.0 (CH), 110.8 (CH), 112.3 (CH), 115.6 (C), 129.9 (CH), 138.9 (C), 145.9 (CH), 147.7 (C), 148.3 (C), 160.26 (C), 163.7 (C), 169.6 (C). ESI-HRMS (*m/z*) calculated for [M + H]⁺ ion species C₁₉H₂₃N₄O₂ = 339,1815, found 339,1816. Anal. C₁₉H₂₂N₄O₂ (C,H,N).

2-(tert-Butyl)-3-chloro-N-(3-methoxyphenyl)-7-methylpyrazolo[1,5-*a*]pyrimidine-6-carboxamide (22c).: Yield = 7%; mp = 164–166 °C (brown solid). ¹H NMR (400 MHz, CDCl₃) δ 1.51 (s, 9H, C-(CH₃)₃), 2.98 (s, 3H, CH₃), 3.83 (s, 3H, OCH₃), 6.74 (dd, 1H, Ar, *J*₁ = 2.0 and *J*₂ = 8.0), 7.10 (d, 1H, Ar, *J* = 7.6), 7.27 (t, 1H, Ar, *J* = 8.4), 7.38 (s, 1H, Ar), 7.91 (exch br s, 1H, NH), 8.59 (s, 1H, Ar). ¹³C NMR (100 MHz, CDCl₃) δ 14.2 (CH₃), 28.5 (CH₃),

34.1 (C), 55.4 (CH₃), 98.2 (C), 111.0 (CH), 112.3 (CH), 129.9 (CH), 138.7 (C), 144.3 (C), 146.8 (CH), 148.1 (C), 160.3 (C), 162.7 (C). ESI-HRMS (*m/z*) calculated for [M + H]⁺ ion species C₁₉H₂₂ClN₄O₂ = 373,1426, found 373,1421. Anal. C₁₉H₂₁ClN₄O₂ (C,H,N).

N-(3-Methoxybenzyl)-2,7-dimethylpyrazolo[1,5-a]pyrimidine-6-carboxamide

(22d).: Yield = 6%; mp = 125–127 °C (brown solid). ¹H NMR (400 MHz, CDCl₃) δ 2.52 (s, 3H, CH₃), 2.95 (s, 3H, CH₃), 3.79 (s, 3H, OCH₃), 4.60 (d, 2H, CH₂, *J* = 5.6), 6.46 (m, 2H, Ar + NH), 6.83 (d, 1H, Ar, *J* = 8.0), 6.88 (s, 1H, Ar), 6.92 (d, 1H, Ar, *J* = 7.6), 7.26 (m, 1H, Ar), 8.43 (s, 1H, Ar). ¹³C NMR (100 MHz, CDCl₃) δ 13.3 (CH₃), 16.1 (CH₃), 43.6 (CH₂), 55.9 (CH₃), 96.7 (CH), 111.0 (CH), 112.3 (CH), 119.3 (CH), 126.9 (C), 129.5 (CH), 138.3 (C), 141.7 (C), 150.8 (C), 155.8 (C), 157.9 (CH), 160.4 (C), 167.9 (C). ESI-HRMS (*m/z*) calculated for [M + H]⁺ ion species C₁₇H₁₉N₄O₂ = 311,1503, found 311,1501. Anal. C₁₇H₁₈N₄O₂ (C,H,N).

2-(tert-Butyl)-N-(3-methoxybenzyl)-7-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide

(22e).: Yield = 13%; oil. ¹H NMR (400 MHz, CDCl₃) δ 1.39 (s, 9H, C-(CH₃)₃), 2.98 (s, 3H, CH₃), 3.80 (s, 3H, OCH₃), 4.62 (d, 2H, CH₂, *J* = 5.6), 6.38 (exch br s, 1H, NH), 6.52 (s, 1H, Ar), 6.81–6.94 (m, 3H, Ar), 7.27 (m, 1H, Ar), 8.44 (s, 1H, Ar). ¹³C NMR (100 MHz, CDCl₃) δ 14.9 (CH₃), 30.3 (CH₃), 33.2 (C), 44.3 (CH₂), 55.3 (CH₃), 93.8 (CH), 113.2 (CH), 113.5 (CH), 120.0 (CH), 126.8 (C), 130.0 (CH), 139.2 (C), 141.8 (C), 145.9 (CH), 147.6 (C), 150.8 (C), 153.5 (C), 160.1 (C), 165.3 (C). ESI-HRMS (*m/z*) calculated for [M + H]⁺ ion species C₂₀H₂₅N₄O₂ = 353,1972, found 353,1977. Anal. C₂₀H₂₄N₄O₂ (C, H,N).

2-(tert-Butyl)-3-chloro-N-(3-methoxybenzyl)-7-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide (22f).

(22f).: Yield = 21%; mp = 140–141 °C (brown solid). ¹H NMR (400 MHz, CDCl₃) δ 1.50 (s, 9H, C-(CH₃)₃), 2.97 (s, 3H, CH₃), 3.81 (s, 3H, OCH₃), 4.63 (d, 2H, CH₂, *J* = 5.6), 6.20 (exch br s, 1H, NH), 6.85 (dd, 1H, Ar, *J*₁ = 2.4 and *J*₂ = 8.0), 6.90 (d, 1H, Ar, *J* = 2.0), 6.93 (d, 1H, Ar, *J* = 7.6), 7.83 (t, 1H, Ar, *J* = 7.8), 8.51 (s, 1H, Ar). ¹³C NMR (100 MHz, CDCl₃) δ 14.2 (CH₃), 28.5 (CH₃), 44.4 (CH₂), 55.3 (CH₃), 98.2 (C), 113.3 (CH), 113.6 (CH), 115.9 (C), 120.0 (CH), 130.0 (CH), 139.0 (CH), 144.5 (C), 146.9 (CH), 147.9 (C), 160.1 (C), 162.5 (C), 164.9 (C). ESI-HRMS (*m/z*) calculated for [M + H]⁺ ion species C₂₀H₂₄ClN₄O₂ = 387,1582, found 387,1578. Anal. C₂₀H₂₃ClN₄O₂ (C,H,N).

6-Acetyl-N-(3-methoxyphenyl)-7-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide

(22g).: Yield = 7%; mp = 178–179 °C (colourless solid). ¹H NMR (400 MHz, CDCl₃) δ 2.76 (s, 3H, CH₃), 3.21 (s, 3H, COCH₃), 3.85 (s, 3H, OCH₃), 6.68 (m, 1H, Ar), 7.16 (m, 1H, Ar), 7.22–7.27 (m, 1H, Ar), 7.53 (s, 1H, Ar), 8.83 (s, 1H, Ar), 9.04 (s, 1H, Ar), 9.83 (exch br s, 1H, NH). ¹³C NMR (100 MHz, CDCl₃) δ 15.5 (CH₃), 29.9 (CH₃), 55.3 (CH₃), 90.7 (C), 105.4 (CH), 110.0 (CH), 112.0 (CH), 119.8 (C), 129.6 (CH), 138.9 (C), 142.5 (C), 145.4 (C), 148.8 (CH), 150.7 (CH), 152.4 (C), 159.9 (C), 196.6 (C) ESI-HRMS (*m/z*) calculated for [M + H]⁺ ion species C₁₇H₁₇N₄O₃ = 325,1295, found 325,1296. Anal. C₁₇H₁₆N₄O₃ (C,H,N).

6-Acetyl-N-(3-methoxybenzyl)-7-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide

(22h).: Yield = 5%; mp = 164–166 °C (colorless solid). ¹H NMR (400 MHz, CDCl₃) δ 2.71 (s, 3H, CH₃), 3.20 (s, 3H, COCH₃), 3.79 (s, 3H, OCH₃), 4.71 (d, 2H, CH₂, *J* = 6.0),

6.82 (dd, 1H, Ar, $J_1 = 2.4$ and $J_2 = 8.4$), 6.94 (m, 1H, Ar), 6.98 (d, 1H, Ar, $J = 7.2$), 7.26 (t, 1H, Ar, $J = 7.6$), 8.24 (exch br s, 1H, NH), 8.81 (s, 1H, Ar), 8.92 (s, 1H, Ar). ^{13}C NMR (100 MHz, CDCl_3) δ 16.6 (CH_3), 29.1 (CH_3), 43.9 (CH_2), 55.9 (CH_3), 105.1 (C), 111.0 (CH), 112.3 (CH), 119.2 (CH), 119.7 (C), 129.5 (CH), 138.3 (C), 142.6 (C), 145.5 (CH), 145.8 (C), 156.2 (CH), 160.4 (C), 167.9 (C), 196.7 (C). ESI-HRMS (m/z) calculated for $[\text{M} + \text{H}]^+$ ion species $\text{C}_{18}\text{H}_{19}\text{N}_4\text{O}_3 = 339,1452$, found 339,1458. Anal. $\text{C}_{18}\text{H}_{18}\text{N}_4\text{O}_3$ (C,H,N).

3.2. HNE inhibition assay

All compounds were dissolved in 100% DMSO at 5 mM stock concentrations. The final concentration of DMSO in the reactions was 1%, and this level of DMSO had no effect on enzyme activity. The HNE inhibition assay was performed in black flat-bottom 96-well microtiter plates. Briefly, a buffer solution containing 200 mM Tris-HCl, pH 7.5, 0.01% bovine serum albumin, and 0.05% Tween-20 and 20 mU/mL of HNE (Calbiochem) was added to wells containing different concentrations of each compound. The reaction was initiated by addition of 25 μM elastase substrate (*N*-methylsuccinyl-Ala-Ala-Pro-Val-7-amino-4-methylcoumarin, Calbiochem) in a final reaction volume of 100 μL /well. Kinetic measurements were obtained every 30 s for 10 min at 25 $^\circ\text{C}$ using a Fluoroskan Ascent FL fluorescence microplate reader (Thermo Electron, MA) with excitation and emission wavelengths of 355 and 460 nm, respectively. For all compounds tested, the concentration of inhibitor that caused 50% inhibition of the enzymatic reaction (IC_{50}) was calculated by plotting % inhibition versus logarithm of inhibitor concentration (at least six points). The data are presented as the mean values of at least three independent experiments with relative standard deviations of < 15%.

3.3. Analysis of compound stability

Spontaneous hydrolysis of selected compounds was evaluated at 20 $^\circ\text{C}$ in 0.05 M phosphate buffer, pH 7.4. Kinetics of hydrolysis was monitored by measuring changes in absorbance spectra over incubation time using a SpectraMax ABS Plus spectrophotometer (Molecular Devices, Sunnyvale, CA). Absorbance (A_t) at the characteristic absorption maxima of each compound was measured at the indicated times until no further absorbance decreases occurred (A_∞). Using these measurements, we created semilogarithmic plots of $\log(A_t - A_\infty)$ vs time, and k' values were determined from the slopes of these plots. Half-conversion times were calculated using $t_{1/2} = 0.693/k'$.

3.4. Molecular modeling

Initial 3D structures of compounds **2e**, **4**, **2p**, **2r**, **13a**, **13c**, and **13e** were built with ChemOffice Professional (Perkin Elmer, Waltham, MA) and refined by molecular mechanics with MM2 force field.⁵⁴ For the docking computations, Molegro Virtual Docker (MVD) software, version 6.0 (CLC Bio, Copenhagen, Denmark), was used as described previously.²⁰ The structure of HNE co-crystallized with a peptide chloromethyl ketone inhibitor (1HNE entry of the Protein Data Bank) determined by X-ray diffraction⁵⁵ was used for the docking studies. The co-crystallized peptide ligand and water molecules were removed from the 1HNE structure. A search for docking poses was performed within a spherical area of 10 Å radius centered at the atom in the five-membered ring of the

co-crystallized inhibitor. Side chains of 42 residues closest to the center of the sphere²⁰ were set flexible, including the residues surrounding HNE binding site: His57, Cys58, Leu99B, Val190, Cys191, Phe192, Gly193, Asp194, Ser195, Ala213, Ser214, Phe215, Val216. Fifteen docking runs were performed for each compound with full flexibility of a ligand around all rotatable bonds and with flexibility of the above-mentioned side chains of the enzyme amino acid residues. Docking poses of each compound were checked for the ability to form a Michaelis complex between the carbonyl moiety in a ligand and the Ser195 hydroxyl group. For this purpose, the important geometric parameters were determined: d_1 [distance O(Ser195)···C between the Ser195 hydroxyl oxygen atom and the ligand carbonyl carbon atom closest to O(Ser195)] and α [angle O(Ser195)···C=O, where C=O is the carbonyl group of a ligand closest to O(Ser195)]⁵⁰ (Fig. 4). The conditions for proton transfer within the key catalytic triad from Ser195 to Asp102 via His57 were also evaluated by the calculation of distances d_2 between the NH hydrogen in His57 and carboxyl oxygen atoms in Asp102, as described in our earlier paper.²⁰ The distance between the OH proton in Ser195 and the pyridine-type nitrogen in His57 is also important for proton transfer. However, the OH group of the Ser195 is easily rotatable about the C–O bond. Hence, we measured distance d_3 between the oxygen atom of Ser195 side chain and the basic nitrogen atom in His57 residue. The effective length of the proton transfer channel was determined as $L = \min(d_2) + d_3$.

3.5. DFT calculations

Single-molecule DFT calculations were performed with the Gaussian 09w program, Revision-D.01 (Gaussian, Inc., Wallingford CT) for compounds **2b**, **2n**, **2o**, **2p**, **2q**, **2r**, **2s**, **4**, **13a**, **13b**, **13c**, and **19** in gas phase. The hybrid B3LYP functional^{56,57} and 6–31+G(d,p) basis set⁵⁸ were used with D3BJ dispersion correction⁵⁹ applied. Vibrational frequency analysis was done for all the optimized geometries in order to ensure attaining energy minima for the molecules.

4. Conclusions

We identified new potent HNE inhibitors with different nitrogen heterocyclic scaffolds that were designed as modifications of effective compounds previously synthesized by our research group.^{20,21} The biological results indicated that the change of position of the nitrogen, as well as the insertion of an additional nitrogen atom in the nuclei of reference compounds **A**, **B**, and **C** did not negatively impact biological activity, since most of the new products exhibited potent HNE inhibitory activity with IC_{50} values in the nanomolar range. The most potent compounds were in the series of 5/7-azaindazoles (**2p**, **2r**, and **4** with IC_{50} = 10, 16, and 21 nM, respectively) and 4/5-azaindoles (**13b**, **13c** with IC_{50} = 23 and 14 nM, respectively). Analysis of chemical stability indicated that the new inhibitors generally had a half-life ($t_{1/2}$) > 1 h and for compounds **2b**, **2o**, **2s**, and **13b**, $t_{1/2}$ was > 4 h. The new azaindazole derivatives of type 2, were stable than the previously described indazoles (i.e., reference compound **A**, which had a $t_{1/2}$ of 21.7 min)²⁰ with the only exception being **2p** ($t_{1/2}$ = 12.2 min). These results suggest that this new scaffold improves chemical stability against spontaneous hydrolysis; however, chemical stability also seems to be related to the substituent at position 3 of the scaffold. In fact, both **2p** and **A**, which differ only in a

nitrogen at position 5 of the scaffold, present a CN group at position 3, which could be responsible for this increased hydrolysis.

The relatively stable compounds **2b**, **2o**, **2s**, and **13b** were well separated from hydrolytically unstable derivatives according to their LUMO energies E(LUMO). Indeed, the unstable compounds had overall lower values of E(LUMO) and, hence, were more prone to reactions with nucleophilic species. Molecular modeling studies confirmed the importance of the Michaelis complex formation for the interaction with the enzyme pocket, and we found that highly active HNE inhibitors were characterized by geometries favorable for acyl-inhibitor complex formation and by relatively short lengths of the proton transfer channel via the catalytic triad. Finally, *in silico* ADMET calculations predicted that most of the new compounds would be optimally absorbed, distributed, metabolized and excreted. Particularly, compounds **2p**, **2r**, **4**, **13b**, and **13c** had excellent predicted ADMET profiles and no noted toxicity problems. Moreover, many of our compounds seem to be well adsorbed by the skin, opening to a new potential and easier route of administration for *in vivo* studies of these new HNE inhibitors.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

This research was supported in part by National Institutes of Health IDeA Program Grants GM110732, GM115371, and GM103474; USDA National Institute of Food and Agriculture Hatch project 1009546; the Montana State University Agricultural Experiment Station; the Tomsk Polytechnic University Competitiveness Enhancement Program (project CEP-SAMT-208/2020); and the Program of Increasing the Competitiveness of TSU (project No. 8.2.10.2018).

References

1. Jampilek J Heterocycles in medicinal chemistry. *Molecules*. 2019;24:3839. 10.3390/molecules24213839.
2. Giovannoni MP, Ciciani G, Cilibrizzi A, et al. Further studies on pyrazolo[10,50:1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as potent and selective human A1 adenosine receptor antagonists. *Eur J Med Chem*. 2015;89:32–41. 10.1016/j.ejmech.2014.10.020. [PubMed: 25462223]
3. Biagini P, Biancalani C, Graziano A, et al. Functionalized pyrazoles and pyrazolo[3,4-d]pyridazinones: Synthesis and evaluation of their phosphodiesterase 4 inhibitory activity. *Bioorg Med Chem*. 2010;18:3506–3517. 10.1016/j.bmc.2010.03.066. [PubMed: 20413313]
4. Vergelli C, Schepetkin IA, Ciciani G, et al. 2-Arylacetamido-4-phenylamino-5-substituted pyridazinones as formyl peptide receptors agonists. *Bioorg Med Chem*. 2016;24:2530–2543. 10.1016/j.bmc.2016.04.019.
5. Guerrini G, Ciciani G, Ciattini S, et al. Pyrazolo[1,5-A]quinazoline scaffold as 5-deaza analogue of pyrazolo[5,1-c][1,2,4]benzotriazine system: Synthesis of new derivatives, biological activity on GABA_A receptor subtype and molecular dynamic study. *J Enzyme Inhib Med Chem*. 2016;31:195–204. 10.3109/14756366.2015.1014475. [PubMed: 25792503]
6. Von Nussbaum F, Li VMJ. Neutrophil elastase inhibitors for the treatment of (cardio) pulmonary diseases: into clinical testing with pre-adaptive pharmacophores. *Bioorg Med Chem*. 2015;25:4370–4381. 10.1016/j.bmc.2015.08.049.
7. Crocetti L, Quinn MT, Schepetkin IA, Giovannoni MP. A patenting perspective on human neutrophil elastase (HNE) inhibitors (2014–2018) and their therapeutic applications. *Expert Opin Ther Pat*. 2019;29:555–578. 10.1080/13543776.2019.1630379. [PubMed: 31204543]

8. [Clinicaltrials.gov](https://clinicaltrials.gov). NCT study code [NCT03636347](https://clinicaltrials.gov/ct2/show/study/NCT03636347), [NCT03679598](https://clinicaltrials.gov/ct2/show/study/NCT03679598), [NCT02669251](https://clinicaltrials.gov/ct2/show/study/NCT02669251), (2020).Suns.
9. Von Nussbaum F, Li VM-J, Allerheiligen S, et al. Freezing the bioactive conformation to boost potency: the identification of BAY 85–8501, a selective and potent inhibitor of human neutrophil elastase for pulmonary diseases. *ChemMedChem*. 2015;10: 1163–1173. 10.1002/cmdc.201500131. [PubMed: 26083237]
10. Carnini C, Brogin G, Patacchini R, et al. CHF6333: pharmacological and pharmacokinetic characterization of a novel potent inhaled inhibitor of neutrophil elastase. *Am J Respir Crit Care Med*. 2017;195:A4420.
11. [Clinicaltrials.gov](https://clinicaltrials.gov). NCT study code [NCT04010799](https://clinicaltrials.gov/ct2/show/study/NCT04010799); 2020.
12. Bayer Corp: Prolastin. Company World Wide Web Site. Available from: <http://edoc.com/prolastin>; 2002.
13. Iwata K, Doi A, Ohji G, et al. Effect of neutrophil elastase inhibitor (sivelestat sodium) in the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): a systematic review and meta-analysis. *Intern Med*. 2010;49: 2423–2432. 10.2169/internalmedicine.49.4010. [PubMed: 21088343]
14. Giovannoni MP, Schepetkin IA, Crocetti L, et al. Cinnoline derivatives as human neutrophil elastase inhibitors. *J Enzyme Inhib Med Chem*. 2016;31:628–639. 10.3109/14756366.2015.1057718. [PubMed: 26194018]
15. Crocetti L, Bartolucci G, Cilibrizzi A, et al. Synthesis and analytical characterization of new thiazol-2-(3H)-ones as human neutrophil elastase (HNE) inhibitors. *Chem Cent J*. 2017;11:127. 10.1186/s13065-017-0358-1. [PubMed: 29214393]
16. Giovannoni MP, Schepetkin IA, Quinn MT, et al. Synthesis, biological evaluation, and molecular modelling studies of potent human neutrophil elastase (HNE) inhibitors. *J Enzyme Inhib Med Chem*. 2018;33:1108–1124. 10.1080/14756366.2018.1480615. [PubMed: 29969929]
17. Giovannoni MP, Crocetti L, Cantini N, et al. New 3-unsubstituted Isoxazolones as Potent Human Neutrophil Elastase Inhibitors: Synthesis and Molecular Dynamic Simulation. *Drug Dev Res*. 2020;81:338–349. 10.1002/ddr.21625. [PubMed: 31800122]
18. Crocetti L, Schepetkin IA, Ciciani G, et al. Synthesis and pharmacological evaluation of indole derivatives as Deaza analogues of potent human neutrophil Elastase inhibitors. *Drug Dev Res*. 2016;77:285–299. 10.1002/ddr.21323. [PubMed: 27474878]
19. Crocetti L, Giovannoni MP, Schepetkin IA, et al. Design, synthesis and evaluation of N-Benzoylindazole derivatives and analogues as inhibitors of human neutrophil elastase. *Bioorg Med Chem*. 2011;19:4460–4472. 10.1016/j.bmc.2011.06.036. [PubMed: 21741848]
20. Crocetti L, Schepetkin IA, Cilibrizzi A, et al. Optimization of N-benzoylindazole derivatives as inhibitors of human neutrophil Elastase. *J Med Chem*. 2013;56: 6259–6272. 10.1021/jm400742j. [PubMed: 23844670]
21. Crocetti L, Giovannoni MP, Schepetkin IA, et al. 1H-pyrrolo[2,3-b]pyridine: A new scaffold for human neutrophil elastase (HNE) inhibitors. *Bioorg Med Chem*. 2018;26: 5583–5595. 10.1016/j.bmc.2018.09.034. [PubMed: 30385225]
22. Giovannoni MP, Cantini N, Crocetti L, et al. Further modifications of 1H-pyrrolo[2,3-b]pyridine derivatives as inhibitors of human neutrophil elastase. *Drug Dev Res*. 2019;80:617–628. 10.1002/ddr.21539. [PubMed: 31002441]
23. Schirok H, Griebenow N, Füstner C, Dilmac AM. Use of 3-(trifluoromethyl)-1H-pyrazolo-[3,4-b]pyridine as a versatile building block. *Tetrahedron*. 2005;71: 5597–5601. 10.1016/j.tet.2015.06.050.
24. Aranov A, Lauffer DJ, Li P, Tomlinson RC. Compositions Useful As Inhibitors of Protein Kinases. PCT WO 2005/028475 A2; 2005.
25. Kawase M, Koyanagi J, Saito S. Site-selective trifluoroacetylation of dimethylamino-substituted pyridines and its use as a building block for trifluoromethyl-containing heterocycles. *Chem Pharm Bull*. 1999;47:718–719. 10.1248/cpb.47.718.
26. Hert J, Hunziker D, Kuehne H, et al. Preparation of phenoxymethyl-heterocyclic compounds as autotaxin (ATX) inhibitors. PCT Int Appl. WO 2017037146 A1 20170309, 2017.
27. Tucker TJ, Sisko JT, Tynebor RM, et al. Discovery of 3-{5-[(6-amino-1H-pyrazolo [3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally

- bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses. *J Med Chem.* 2008;51:6503–6511. 10.1021/jm800856c. [PubMed: 18826204]
28. Lynch BM, Misbahul AI, Teo HC, Pedrotti F. Pyrazolo[3,4-b]pyridines: Synthesis, reactions, and nuclear magnetic resonance spectral. *Can J Chem.* 1988;66:420–428. 10.1139/v88-074.
29. Lapa GB, Bekker OP, Mirchink EP, Danilenko VN, Preobrazhenskaya MN. Regioselective acylation of congeners of 3-amino-1H-pyrazolo[3,4-b]quinolines, their activity on bacterial serine/threonine protein kinases and in vitro antibacterial (including antimycobacterial) activity. *J Enzyme Inhib Med Chem.* 2013;28: 1089–1091. 10.3109/14756366.2012.716056.
30. Bradbury RH, Hales NJ, Rabow AA. Bicyclic derivatives for use in the treatment of androgen receptor associated conditions and their preparation. *PTC Int Appl.* WO 2009/081197, 2009.
31. Nakano H, Saito N, Parker L, et al. Rational Evolution of a Novel Type of Potent and Selective Proviral Integration Site in Moloney Murine Leukemia Virus Kinase 1 (PIM1) Inhibitor from a Screening-Hit Compound. *J Med Chem.* 2012;55:5151–5164. 10.1021/jm3001289. [PubMed: 22540945]
32. Clark BAJ, Parrick J, West PJ, Kelly AK. Diazaindenes (azaindoles). Part III. Reactions of Vilsmeier reagents leading to 3-formyl-1,6-diazaindenes and -1,4-diazabenz[f]indene. *J Chem Soc C.* 1970;3:498–501. 10.1039/J39700000498.
33. Clark BAJ, Parrick J, Dorgan RJJ. Formation of certain substituted 5H-pyrrolo[2,3-b] pyrazines by thermal cyclization of pyrazinylhydrazones and a route to 5H-pyrazino [2,3-b]indole; a synthesis of 5H-pyrrolo[2,3-b]pyrazine and some of its properties. *J Chem Soc, Perkin Trans.* 1976;1(13):1361–1363. 10.1039/P19760001361.
34. Bruni F, Selleri S, Costanzo A, Guerrini G, Casilli ML, Giusti L. Reactivity of 7-(2-dimethylaminovinyl)pyrazolo[1,5-a]pyrimidines: synthesis of pyrazolo[1,5-a]pyrido [3,4-e]pyrimidine derivatives as potential benzodiazepine receptor ligands. 2. *J Heterocycl Chem.* 1995;32:291–298. 10.1002/jhet.5570310516.
35. Bruni F, Chimichi S, Cosimelli B, Costanzo A, Guerrini G, Selleri S. A new entry to pyrazolo[1,5-a]pyrido[3,4-e]pyrimidine derivatives. *Heterocycles.* 1990;31: 1141–1149. 10.3987/COM-90-5408.
36. Bartroli J, Turmo E, Alguero M, et al. New Azole Antifungals. 2. Synthesis and Antifungal Activity of Heterocyclecarboxamide Derivatives of 3-Amino-2-aryl-1-azolyl-2-butanol. *J Med Chem.* 1998;41:1855–1868. 10.1021/jm970726e. [PubMed: 9599236]
37. Kato N, Oka M, Murase T, et al. Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl} amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor. *Bioorg Med Chem.* 2011;19:7221–7227. 10.1016/j.bmc.2011.09.043. [PubMed: 22019046]
38. Goldfarb DS. Method using lifespan-altering compounds for altering the lifespan of eukaryotic organisms, and screening for such compounds. *U.S. Pat Appl Publ US 20090163545 A1 20090625 2009.*
39. Schepetkin IA, Khlebnikov AI, Quinn MT. N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. *J Med Chem.* 2007;50:4928–4938. 10.1021/jm070600+. [PubMed: 17850059]
40. Soderberg T *Organic Chemistry with a Biological Emphasis Volume II.* University of Minnesota Morris Digital Well: Chemistry Publications; 2019.
41. Takahashi Y, Ikeda H, Kanase Y, et al. Elucidation of the E-Amide Preference of N-Acyl Azoles. *J Org. Chem* 2017;82:11370–11382. 10.1021/acs.joc.7b01759. [PubMed: 28968504]
42. Staab HA. *New Methods of Preparative Organic Chemistry IV. Syntheses Using Heterocyclic Amides (Azolides).* *Angew Chem Int Ed Engl.* 1962;1:351–367. 10.1002/anie.196203511.
43. Groutas WC, Kuang R, Venkataraman R, Epp JB, Ruan S, Prakash O. Structure-based design of a general class of mechanism-based inhibitors of the serine proteinases employing a novel amino acid-derived heterocyclic scaffold. *Biochemistry.* 1997;36: 4739–4750. 10.1021/bi9628937. [PubMed: 9125494]
44. Burgi HB, Dunitz JD, Lehn JM, Wipff G. Stereochemistry of reaction paths at carbonyl centers. *Tetrahedron.* 1974;30:1563–1572. 10.1016/S0040-4020(01)90678-7.

45. Vergely I, Laugaa P, Reboud-Ravaux M. Interaction of human leukocyte elastase with a N-aryl azetidinone suicide substrate: conformational analyses based on the mechanism of action of serine proteinases. *J Mol Graphics*. 1996;14:158–167. 10.1016/S0263-7855(96)00057-4.
46. Peters MB, Merz KM. Semiempirical comparative binding energy analysis (SE-COMBINE) of a series of trypsin inhibitors. *J Chem Theory Comput*. 2006;2:383–399. 10.1021/ct050284j. [PubMed: 26626526]
47. Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. *Sci Rep*. 2017;7:42717. 10.1038/srep42717. [PubMed: 28256516]
48. Pires DEV, Blundell TL, Ascher DB. pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. *J Med Chem*. 2015;58:4066–4072. 10.1021/acs.jmedchem.5b00104. [PubMed: 25860834]
49. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv Drug Delivery Rev*. 1997;23:3–25. 10.1016/S0169-409X(96)00423-1.
50. Ghose AK, Viswanadhan VN, Wendoloski JJ. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. *J Comb Chem*. 1999;1:55–68. 10.1021/cc9800071. [PubMed: 10746014]
51. Egan WJ, Merz KM, Baldwin JJ. Prediction of drug absorption using multivariate statistics. *J Med Chem*. 2000;43:3867–3877. 10.1021/jm000292e. [PubMed: 11052792]
52. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KM, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. *J Med Chem*. 2002;45:2615–2623. 10.1021/jm020017n. [PubMed: 12036371]
53. Muegge I, Heald SL, Brittelli D. Simple selection criteria for drug-like chemical matter. *J Med Chem*. 2001;4:1841–1846. 10.1021/jm015507e.
54. Vanommeslaeghe K, Guvench O, MacKerell AD Jr. Molecular Mechanics. *Curr Pharm Des*. 2014;20:3281–3292. 10.2174/13816128113199990600. [PubMed: 23947650]
55. Navia MA, McKeever BM, Springer JP, et al. Structure of human neutrophil elastase in complex with a peptide chloromethyl ketone inhibitor at 1.84 Å resolution. *Proc Natl Acad Sci USA*. 1989;86:7–11. 10.1073/pnas.86.1.7. [PubMed: 2911584]
56. Becke AD. A new mixing of Hartree-Fock and local density-functional theories. *J Chem Phys*. 1993;98:5648–5652. 10.1063/1.464913.
57. Stephens PJ, Devlin FJ, Chabalowski CF, Frisch MJ. Ab initio calculation of vibrational absorption and circular dichroism spectra using density functional force fields. *J Phys Chem*. 1994;98:11623–11627. 10.1021/j100096a001.
58. Foresman JB, Frisch AE. Exploring chemistry with electronic structure methods. 3rd edition. Gaussian Inc; 2015.
59. Grimme S, Ehrlich S, Goerigk L. Effect of the damping function in dispersion corrected density functional theory. *J Comp Chem*. 2011;32:1456–1465. 10.1002/jcc.21759. [PubMed: 21370243]




Fig. 1.
Indazole and pyrrolo[2,3-*b*]pyridine derivative modification.




Fig. 2. Analysis of changes in compound absorbance resulting from spontaneous hydrolysis of **4**. The changes in absorbance spectra of the compounds ($20\ \mu\text{M}$ in $0.05\ \text{M}$ phosphate buffer, pH 7.4, $20\ ^\circ\text{C}$) were monitored over time in solution.




Fig. 3. Surfaces of LUMO (isovalue 0.02) for compounds **2b** (A) and **2r** (B) calculated by the DFT method at B3LYP/6-31+G(d,p) level.




Fig. 4. Interaction of a carbonyl-containing ligand $XC(O)Y$ with the HNE catalytic triad (Ser195, His57, and Asp102). Distance d_1 and angle α determine conditions for the Michaelis complex formation. The value of α was measured as an angle between C(carbonyl)···O(Ser195) axis and C=O bond. Distances d_2 and d_3 influence on the proton transfer from Ser195 to Asp102. Length of the proton transfer channel was calculated as $L = \min(d_2) + d_3$.




Fig. 5. Docking poses of **2e**, **2p** and reference compound **A**. **Panel A.** Docking poses of **2e** (violet), **2p** (light blue), and reference compound **A** (green). Co-crystallized methoxysuccinyl-Ala-Ala-Pro-Ala chloromethyl ketone (MSACK) is shown in yellow sticks. Residues within 4 Å from the co-crystallized ligand are visible. **Panel B.** Docking pose of compound **2e**. **Panel C.** Docking pose of compound **2p**. For **Panels B** and **C**, residues within 4 Å of the pose are visible. **Panel D.** Docking pose of compound **2p**. The semi-transparent surface of HNE is shown.




Fig. 6. Docking pose of compound **4** (**Panel A**) and **2r** (**Panel B**). For both panels, residues within 4 Å of the pose are visible.




Fig. 7. Docking poses of **13e**, **13a**, **13c**, and reference compound **B**. **Panel A.** Docking poses of compounds **B** (magenta), **13e** (dark green), **13a** (light blue), and **13c** (orange). Co-crystallized MSACK is shown in yellow sticks. Residues within 4 Å of the co-crystallized ligand are visible. **Panel B.** Docking pose of compound **13e**. **Panel C.** Docking pose of compound **13a**. **Panel D.** Docking pose of compound **13c**. For **Panels B-D** residues within 4 Å of the pose are visible.





Fig. 8. BOILED-Egg plot. Points located in the BOILED-Egg's yellow are the compounds predicted to permeate the BBB passively, differently the ones in the white are the molecules predicted to be only passively absorbed by the gastrointestinal tract. Blue dots indicate molecules expected to be refluxed from the central nervous system (CNS) by the P-glycoprotein, whereas the red ones are not transported by the P-glycoprotein.




1	R ₃	N
a	CF ₃	7
b	CN	7
c	COOEt	7
d	COOiPr	7
e	CF ₃	5
f	CN	5
g	COOEt	5
h	CH ₃	5


2	N	R ₃	X	R ₁
a	7	CF ₃	CO	m-CH ₃ -Ph
b	7	CF ₃	CO	cC ₃ H ₅
c	7	CN	CH ₂	Ph
d	7	CN	CO	Ph
e	7	CN	CO	m-CH ₃ -Ph
f	7	CN	CO	p-CH ₃ -Ph
g	7	CN	CO	cC ₃ H ₅
h	7	CN	CO	cC ₅ H ₉
i	7	CN	CO	cC ₆ H ₁₁
l	7	COOEt	CO	m-CH ₃ -Ph
m	7	COOiPr	CO	m-CH ₃ -Ph
n	5	CF ₃	CO	m-CH ₃ -Ph
o	5	CF ₃	CO	cC ₃ H ₅
p	5	CN	CO	m-CH ₃ -Ph
q	5	CN	CO	cC ₃ H ₅
r	5	COOEt	CO	m-CH ₃ -Ph
s	5	COOEt	CO	cC ₃ H ₅
t	5	CH ₃	CO	m-CH ₃ -Ph

Scheme 1. Reagents and Conditions:

(a) for **2a,b,l-o,r-t**: R-COCl, Et₃N, anhydrous CH₂Cl₂, 0 °C, 2 h, then r.t., 2 h; for **2c**: Benzyl bromide, anhydrous CH₃CN, K₂CO₃, reflux, 4 h; for **2d**: Ph-COOH, dry THF, HOBt, Et₃N, DCC, 0 °C, 30', then r.t., 48 h; for **2e-i,p,q**: dry THF, NaH, 0 °C, 30', then R-COCl, r.t., o/n.

**Scheme 2. Reagents and Conditions:**

(a) dry THF, NaH, 0 °C, 30', then cC₃H₅-COCl, r.t., o/n; (b) HCl 37%, SnCl₂·2H₂O, r.t., 30'; (c) Et₃N, DMF/1,4-Dioxane, R-COCl, 50 °C, 4 h; (d) CH₃COCl, Et₃N, anhydrous CH₂Cl₂, 0 °C, 2 h, then r.t., 2 h.




10-12	N
a	4
b	5
c	6


13	N	R ₁
a	4	m-CH ₃ -Ph
b	4	cC ₃ H ₅
c	5	m-CH ₃ -Ph
d	5	cC ₃ H ₅
e	6	m-CH ₃ -Ph
f	6	cC ₃ H ₅

Scheme 3. Reagents and Conditions:

(a) NH₂OH·HCl, H₂O, 60 °C, 30 min; NaHCO₃, reflux, 4 h; (b) POCl₃, reflux, 2 h; (c) R-COCl, Et₃N, anhydrous CH₂Cl₂, 0 °C, 2 h, then r.t., 2 h.

**Scheme 4. Reagents and Conditions:**


(a) R-COCl, Et₃N, anhydrous CH₂Cl₂, 0 °C, 2 h, then r.t., 2 h; (b) HTMA, glacial CH₃COOH, reflux, 2 h; (c) NH₂OH·HCl, H₂O, 60 °C, 30 min; NaHCO₃, reflux, 4 h; (d) POCl₃, reflux, 2 h.



22	R ₂	R ₃	R
a	CH ₃	H	m-(OCH ₃)-Ph
b	t-Bu	H	m-(OCH ₃)-Ph
c	t-Bu	Cl	m-(OCH ₃)-Ph
d	CH ₃	H	m-(OCH ₃)-Bz
e	t-Bu	H	m-(OCH ₃)-Bz
f	t-Bu	Cl	m-(OCH ₃)-Bz
g	-	-	m-(OCH ₃)-Ph
h	-	-	m-(OCH ₃)-Bz


Scheme 5. Reagents and Conditions:

(a) NCS, CCl₄, (PhCOO)₂, reflux, 12 h; b) NaOH 6 N, reflux, 2 h; c) CCl₃CN, PPh₃, dry DCM, r.t., 4 h then appropriate amine (m-anisidine or 3-methoxybenzylamine), Et₃N, r.t., 12 h.

Table 1HNE inhibitory activity of compounds **2a-t**, **4**, **6**, **7**, and **9**.**2a-t**
4, 6, 7, 9

Compound	N	R ₃	X	R ₁	IC ₅₀ (μM) ^a
2a	7	CF ₃	CO	m-CH ₃ -Ph	0.42 ± 0.12
2b	7	CF ₃	CO	cC ₃ H ₅	0.050 ± 0.01
2c	7	CN	CH ₂	Ph	N.A. ^b
2d	7	CN	CO	Ph	0.16 ± 0.05
2e	7	CN	CO	m-CH ₃ -Ph	0.33 ± 0.03
2f	7	CN	CO	p-CH ₃ -Ph	1.5 ± 0.051
2g	7	CN	CO	cC ₃ H ₅	0.034 ± 0.012
2h	7	CN	CO	cC ₅ H ₉	0.14 ± 0.04
2i	7	CN	CO	cC ₆ H ₁₁	1.1 ± 0.22
2l	7	COOEt	CO	m-CH ₃ -Ph	2.0 ± 0.44
2m	7	COOiPr	CO	m-CH ₃ -Ph	0.98 ± 0.31
2n	5	CF ₃	CO	m-CH ₃ -Ph	0.033 ± 0.011
2o	5	CF ₃	CO	cC ₃ H ₅	0.087 ± 0.021
2p	5	CN	CO	m-CH ₃ -Ph	0.010 ± 0.003
2q	5	CN	CO	cC ₃ H ₅	0.079 ± 0.023
2r	5	COOEt	CO	m-CH ₃ -Ph	0.016 ± 0.005
2s	5	COOEt	CO	cC ₃ H ₅	0.069 ± 0.026
2t	5	CH ₃	CO	m-CH ₃ -Ph	0.760 ± 0.14
4	7	NO ₂	CO	cC ₃ H ₅	0.021 ± 0.002
6	7	NH ₂	CO	cC ₃ H ₅	9.9 ± 1.3
7	7	NHCO-cC ₃ H ₅	CO	cC ₃ H ₅	1.5 ± 0.14
9	7	NHCO-m-CH ₃ -Ph	CO	CH ₃	25.2 ± 1.3
Sivelestat					0.050 ± 0.020
A²⁰	–	CN	CO	m-CH ₃ -Ph	0.007 ± 0.0015


^aIC₅₀ values are presented as the mean ± SD of three independent experiments.^bN.A.: no inhibitory activity was found at the highest concentration of compound tested (50 μM).

Table 2HNE inhibitory activity of compounds **13a-f**, **15b**, and **19b**.

Compound	N	R ₁	IC ₅₀ (μM) ^a
13a	4	m-CH ₃ -Ph	0.089 ± 0.034
13b	4	cC ₃ H ₅	0.023 ± 0.004
13c	5	m-CH ₃ -Ph	0.014 ± 0.004
13d	5	cC ₃ H ₅	0.097 ± 0.01
13e	6	m-CH ₃ -Ph	0.194 ± 0.053
13f	6	cC ₃ H ₅	0.183 ± 0.044
15b	–	H	7.9 ± 2.5
19b	–	CN	0.056 ± 0.018
Sivelestat			0.050 ± 0.020
B ²¹	7	m-CH ₃ -Ph	0.015 ± 0.004
C ²¹	7	cC ₃ H ₅	0.087 ± 0.021

^aIC₅₀ values are presented as the mean ± SD of three independent experiments.

Table 3

HNE inhibitory activity of compounds **22a-h**.

Compound	R	R ₂	R ₃	IC ₅₀ (μM) ^a
22a	m-(OCH ₃)-Ph	CH ₃	H	N.A. ^b
22b	m-(OCH ₃)-Ph	<i>t</i> -Bu	H	N.A. ^b
22c	m-(OCH ₃)-Ph	<i>t</i> -Bu	Cl	N.A. ^b
22d	m-(OCH ₃)-Bn	CH ₃	H	N.A. ^b
22e	m-(OCH ₃)-Bn	<i>t</i> -Bu	H	N.A. ^b
22f	m-(OCH ₃)-Bn	<i>t</i> -Bu	Cl	N.A. ^b
22 g	m-(OCH ₃)-Ph	-	-	N.A. ^b
22 h	m-(OCH ₃)-Bn	-	-	N.A. ^b
Sivelestat				0.050 ± 0.020

^aIC₅₀ values are presented as the mean ± SD of three independent experiments.^bN.A.: no inhibitory activity was found at the highest concentration of compound tested (50 μM).

Table 4

Half-life ($t_{1/2}$) for the spontaneous hydrolysis of selected derivatives. LUMO energies of the compounds calculated by DFT B3LYP/6-31 + G(d,p).

Compound	$t_{1/2}$ (min)	E(LUMO), eV
2b	880.0 ± 77.5	-2.376
2n	106.6 ± 2.4	-2.547
2o	386.1 ± 43.2	-2.386
2p	12.2 ± 4.0	-2.819
2q	79.0 ± 15.6	-2.743
2r	147.0 ± 12.3	-2.536
2s	436.8 ± 50.4	-2.418
4	93.8 ± 7.6	-3.374
13a	76.6 ± 1.8	-2.414
13b	268.3 ± 29.3	-2.242
13c	163.3 ± 8.1	-2.484
19b	100.6 ± 5.2	-2.604

Table 5

HNE inhibitory activity of selected compounds and geometric parameters of the enzyme–inhibitor complexes predicted by molecular modelling.^a

Compound	IC ₅₀ (nM)	α (°)	\AA			
			d ₁	d ₂	d ₃	L
2e	330	76.3	3.620	2.196, 3.606	3.291	5.487
4	21	85.2	3.298	2.349, 3.883	3.294	5.643
2p	10	89.8	3.001	1.790, 3.334	2.826	4.616
2r	16	86.7	2.946 ^b	1.769, 3.340	2.856	4.625
13e	194	64.9	3.622	1.857, 3.396	2.872	4.729
13a	89	79.7	3.256	4.852, 5.345	2.478	7.330
13c	14	140.0	4.324	1.790, 3.334	2.815	4.605

^aGeometric parameters correspond to the formation of Michaelis complex with the ester carbonyl group.

^bThe indicated d₁ value corresponds to the carbonyl carbon atom of the ester function of compound **2r**. For amide carbon atom of this compound, the d₁ distance equals 3.817 Å.